## Contents

1. Supplemental Methods	3
1.1.Search Strategy	3
1.2. Study Selection	21
1.3. Data Extraction	22
1.4. Quality Assessment	22
1.5. Data Analysis	22
1.5.1 Statistical Analysis	22
1.5.2 Additional Subgroup Analysis	22
2. Supplemental eResults	23
2.1 Studies With Insufficient Numbers for Meta-Analysis	23
2.2 Risk of Death – Other Subgroup Analyses	23
2.3 Risk of ICU – Sensitivity and Subgroup Analyses	23
2.4 Risk of Any Combination of Severity Outcomes (Death, Among Patients With IC/IS Conditions Compared With Pat	•
2.5. Supplemental eTables	24
2.5.1. Supplemental eTable 1. Inclusion and Exclusion Criteria	for Studies Included in This Analysis 24
2.5.2 Supplemental eTable 2. Omicron Period in the Included S	Studies26
2.5.3. Supplemental eTable 3. Risk of Bias of the Included Stud	dies Using NOS and JBI Tools30
2.5.4. Supplemental eTable 4. Main and Sensitivity Analyses R	Lesults of the 'Death' Outcome33
2.5.5. Supplemental eTable 5. Main and Population Subgroup for All Population Subgroups of Interest	•
2.5.6. Supplemental eTable 6. Main and Sensitivity Analyses R	esults of the 'Hospitalization' Outcome 35
2.5.7. Supplemental eTable 7. Main and Population Subgroup A Outcome for All Subgroups of Interest	•
2.5.8. Supplemental eTable 8. Main and Sensitivity Analyses R	tesults of the 'ICU Admission' Outcome .37
2.5.9. Supplemental eTable 9. Main and Population Subgroup All Population Subgroups of Interest	•
2.5.10. Supplemental eTable 10. Main and Sensitivity Analyses	s Results of the 'Combined' Outcome39
2.5.11. Supplemental eTable 11. Main and Population Subgrou Outcome for All Population Subgroups of Interest	<u> </u>
2.6. Meta-analyses for Each IC/IS Condition: Forest Plots o and Outcome	
2.6.1. Autoimmune Disease	41
2.6.2. Cancer	45
2.6.3. HIV	49

## Risk of severe COVID-19 outcomes: Immunocompromised SLR and MA (Supplemental Materials)

2.6.4. IC/IS	50
2.6.5. Liver Disease	54
2.6.6. Renal Disease	58
2.6.7. Transplant	62
References	66

## 1 1. Supplemental eMethods

### 1.1. Search Strategy

2

3456789

10 11

12 13

14

15 16

17

The following databases were used for searches: Embase, MEDLINE, PubMed, Europe PMC (including medRix and bioRxiv preprints), Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane COVID-19 Study Register, and the World Health Organization (WHO) COVID-19 Database. Search strategies were structured using search terms related to COVID-19 infection, risk, and burden of illness, in combination with appropriate study design filters, as detailed below. Rolling searches were performed each month for studies available between 1 January 2022 and 13 March 2024, though the WHO COVID-19 database was no longer available before the end date (ceased June 2023). Hand searching was also performed, in which bibliographies of identified studies were checked, and for particularly relevant studies, citation tracking (Google Scholar) was performed.

Searching was carried out using 2 separate search approaches:

Search 1: Burden/risk of COVID-19 infection;

Search 2: Protective effect of vaccination on burden/risk of COVID-19 infection.

The following resources were searched for this systematic review:

Database	Host	Date range	Date searched	S1: Burden results	S2: Vaccine results
January 2024 searches					
Embase	Ovid	2022-2023/12/29	2.1.24	4172	1628
Medline ALL	Ovid	2022-2024/02/02	3.1.24	3385	825
PubMed	NLM	2022-2024/01/03	3.1.24	1047	281
LILACS	www	2022-2024/01/04	4.1.24	38	3
Cochrane COVID Register	www	2022-2024/01/04	4.1.24	3814	1792
Europe PMC, includes bioRxiv & medRxiv	www	2022-2024/01/04	4.1.24	10	10
WHO COVID-19 database	www	2022-2024/01/03	3.1.24	2268	477
January 2024 subtotal				14734	5016
February 2024 update searches					
Embase	Ovid	2022-2024/02/01	1.2.24	460	110
Medline ALL	Ovid	2022-2024/02/01	1.2.24	363	51
PubMed	NLM	2022-2024/02/01	1.2.24	92	20
LILACS	www	2022-2024/02/01	2.2.24	3	0
Cochrane COVID Register	www	2022-2024/02/01	2.2.24	0	1

Europe PMC, includes bioRxiv & medRxiv	www	2022-2024/02/01	1.2.24	0	1
WHO COVID-19 database*	www	Not updated	-	-	-
February 2024 subtotal				918	183
March 2024 update searches					
Embase	Ovid	2022-2024/03/01	1.3.24	404	86
68	Ovid	2022-2024/03/01	1.3.24	386	63
PubMed	NLM	2022-2024/03/01	12.3.24	68	17
LILACS	www	2022-2024/03/01	13.3.24	0	0
Cochrane COVID Register	www	2022-2024/03/01	13.3.24	59	0
Europe PMC, includes bioRxiv & medRxiv	www	2022-2024/03/01	1.3.24	3	0
WHO COVID-19 database*	www	Not updated	-	-	-
March 2024 update subtotal				920	166
Sub total retrieved				16572	5365
Sub total screened				9425	2167
Sub total duplicates				7147	3198
Combined total retrieved					21937
Combined total screened					11592
Combined total duplicates					10345

<sup>\*</sup> WHO COVID-19 database ceased on June 2023, therefore update searches were not necessary.

## Search 1: Burden/risk of COVID-19 infection search strategies

```
21
22
23
24
25
26
27
       Embase (Ovid): 2022-2023/12/29
       Searched 2.1.24
       1
                exp coronavirus disease 2019/
                                                   374674
                sars-related coronavirus/ or exp Severe acute respiratory syndrome coronavirus 2/
                                                                                                        106902
       2
28
       3
                (coronavirinae/ or betacoronavirus/ or coronavirus infection/) and (epidemic/ or pandemic/)
29
                10615
30
       4
                (Coronavirus$ or "covid 19" or 2019-ncov).ti,ab,kw,kf,ot.
                                                                             430070
31
       5
                (2019-ncov or 2019ncov or corona-virus$ or cov19 or cov-19 or 19nCoV or COVID19 or COVID2019
32
       or "COVID-19 2019").ti,ab,kw,kf,ot.
                                                   15833
33
                (ncov$ or "sars cov$" or sarscov$ or "sars coronavirus$" or coronovirus$ or corono$ virus$ or "19-
34
       nCoV$" or 19nCoV$).ti.ab.kw.kf.ot.
                                                   160670
35
36
37
                (SARS2$ or "SARS-2$" or SARScoronavirus$ or SARS-coronavirus$ or SARScoronovirus$ or
       SARS-coronovirus$).ti,ab,kw,kf,ot. 2922
                ("HCoV-19$" or HCoV19$ or "HCoV-2019$" or HCoV2019$).ti,ab,kw,kf,ot.
38
39
       9
                ("2019 novel$" or Ncov$).ti,ab,kw,kf,ot.
                                                            5843
       10
                ("Severe Acute Respiratory Syndrome Coronavirus 2" or "Severe Acute Respiratory Syndrome Corona
40
       Virus 2").ti,ab,kw,kf,ot.
                                 36797
41
                or/1-10 496535
       11
42
43
                ("2022" or "2023" or "2024").ti,ab,ot.
       12
                                                            235450
       13
                11 and 12
                                 26927
44
45
       14
                (strain or strains or variant$ or mutation$).ti,ab,ot,kf,kw.
                                                                             2383716
       15
                11 and 14
                                 36992
46
       16
                exp "SARS-CoV-2 (lineage B.1.1)"/
                                                            8191
47
48
       17
                exp "SARS-CoV-2 Omicron"/
                                                   7250
       18
                (omikron or Omicron or "B.1.1.529" or "B11529" or xbb$).af. 13566
49
       19
                or/16-18 14551
50
       20
                or/13,15,19
                                 63058
51
       21
                Clinical study/
                                 165138
52
53
54
55
56
57
58
       22
                Case control study/
                                          211296
       23
                Family study/
                                 25764
       24
                Longitudinal study/
                                          203445
       25
                Retrospective study/
                                          1544157
                Prospective study/
       26
                                          899644
       27
                Randomized controlled trials/
                                                   267337
       28
                26 not 27
                                 888668
59
                Cohort analysis/ 1096585
       29
60
       30
                (Cohort adj (study or studies)).mp. 493516
61
                (Case control adj (study or studies)).tw.
       31
                                                            171865
62
63
                (follow up adj (study or studies)).tw.
       32
                                                            74874
       33
                (observational adj (study or studies)).tw.
                                                            264634
64
       34
                (epidemiologic$ adj (study or studies)).tw.
                                                            123898
65
       35
                (cross sectional adj (study or studies)).tw.
                                                            356386
66
       36
                or/21-25,28-35
                                 4072059
67
       37
                animal/ or animal experiment/
                                                   4720382
68
       38
                (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
69
       porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or ovine or
70
       monkey or monkeys).ti,ab,ot,hw. 7724982
71
                or/37-387724982
       39
72
73
       40
                human experiment/ or exp humans/ 25973725
                39 not (39 and 40)
       41
                                          5781960
74
75
76
       42
                36 not 41
                                 4009600
                limit 42 to vr="2022 -Current"
       43
                                                   754329
       44
                43 not (letter or editorial or conference or "conference abstract" or "conference paper" or "conference
       review").pt.
                         555478
78
                mortality/ or death/ or "cause of death"/ or survival rate/
       45
                                                                             1478645
```

- (mortalit\$ or death\$ or fatal\$ or survival).ti,ab,ot,kf,kw. exp intensive care/ or exp intensive care unit/ or high dependency unit/ 1066416 (close attention unit\$ or intensive care or respiratory care unit or respiratory care units or special care unit or special care units or high dependency unit or high dependency units).ti,ab,ot,kf,kw. 84 (ICU or ICUs or CCU or CCus or GICU or GICUs or HDU or HDUs or ITU or ITUs).ti,ab,ot,kf,kw. (Hospitaliz\$ or Hospitalis\$ or (hospital adj2 Admission\$) or Critical Care).ti,ab,ot,kf,kw. 716741 hospitalization/ 546684 ("length of stay" or "duration of stay" or "extended stay" or "prolonged stay" or "hospital stay").ti,ab,ot,hw.412206 ("in-patient stay" or "inpatient stay" or "in-patient stays" or "inpatient stays").ti,ab,ot,hw. 7835 or/45-53 5826795 exp risk/ or exp risk factor/ or exp risk assessment/ hazard ratio/ or odds ratio/ 99395 94 mortality risk/ life table/ (risk\$ or danger\$ or association\$ or peril or jeopard\$ or threat\$ or chance or chances or hazard\$ or 97 gamble\$ or probabilit\$ or "at stake" or endanger\$ or associat\$ or likelihood\$ or possibilit\$ or correlation\$ or odds).ti,ab,ot,kf,kw. (morbidit\$ or comorbid\$ or co-morbid\$).ti,ab,ot,kf,kw. (incidence or prevalence or predict\$ or prognosis).ti,ab,ot,kf,kw. (HR or RR or aiRR or aOR or "adjusted OR").ti,ab,ot,kf,kw. 753007
  - The Embase strategy was updated on 1.2.24 (460 records) and 1.3.24 (404 records).

COVID facet based on terms from:

or/55-62 15711755

20 and 54 and 63 and 44 4172

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from: <a href="https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5">https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5</a>

Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-19 — EMBASE (Internet). Available from: <a href="https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/">https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/</a>

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: <a href="https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445">https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445</a>

*Observational study design filter adapted from:* 

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Embase. Edinburgh: SIGN, Last Modified 24/04/17 Available from: <a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters">https://www.sign.ac.uk/what-we-do/methodology/search-filters</a>

Observational Studies - Embase. In: CADTH Search Filters Database. Ottawa: CADTH; 2023 [accessed 7.11.23]: <a href="https://searchfilters.cadth.ca/link/37">https://searchfilters.cadth.ca/link/37</a>

## Medline ALL (Ovid): 2022-2024/01/02 Searched 3.1.24

- 1 exp COVID-19/ 250794
- exp Severe acute respiratory syndrome-related coronavirus/ 166686
- 135 3 coronaviridae/ or exp coronavirus/ 178833
- 4 Betacoronavirus/ 33277

```
137
        5
                 Coronavirus Infections/
                                           46094
138
        6
                 or/3-5
                         185838
139
        7
                 epidemics/ or pandemics/ 139078
140
        8
                 Disease Outbreaks/
                                           92374
141
                 or/7-8 226884
        9
142
                 6 and 9 83151
        10
143
                 (Coronavirus$ or "covid 19" or 2019-ncov).ti,ab,kw,kf,ot.
                                                                             385791
        11
144
                 (2019-ncov or 2019ncov or corona-virus$ or cov19 or cov-19 or 19nCoV or COVID19 or COVID2019
        12
145
        or "COVID-19 2019").ti,ab,kw,kf,ot.
                                                    10202
146
                 (ncov$ or "sars cov$" or sarscov$ or "sars coronavirus$" or coronovirus$ or corono$ virus$ or "19-
        13
147
        nCoV$" or 19nCoV$).ti,ab,kw,kf,ot.
                                                    140222
148
                 (SARS2$ or "SARS-2$" or SARScoronavirus$ or SARS-coronavirus$ or SARScoronovirus$ or
        14
149
        SARS-coronovirus$).ti,ab,kw,kf,ot. 2635
150
        15
                 ("HCoV-19$" or HCoV19$ or "HCoV-2019$" or HCoV2019$).ti.ab.kw.kf.ot.
151
        16
                 ("2019 novel$" or Ncov$).ti,ab,kw,kf,ot.
                                                            5236
152
        17
                 ("Severe Acute Respiratory Syndrome Coronavirus 2" or "Severe Acute Respiratory Syndrome Corona
153
        Virus 2").ti,ab,kw,kf,ot.
                                  36907
154
                 or/1-2,10-17
        18
                                  416995
155
        19
                 ("2022" or "2023" or "2024").ti,ab,ot.
                                                            153808
156
        20
                 18 and 19
                                  17876
157
        21
                 (strain or strains or variant$ or mutation$).ti,ab,ot,kf,kw.
                                                                             1916135
158
        22
                 18 and 21
                                  32095
159
                 (omikron or Omicron or "B.1.1.529" or "B11529" or xbb$).af. 9846
        23
160
        24
                 or/20,22-23
                                  48695
161
        25
                 mortality/ or "cause of death"/ or fatal outcome/ or hospital mortality/ or survival rate/
                                                                                                       388730
162
        26
                 Death/ 20522
163
        27
                 (mortalit$ or death$ or fatal$ or survival).ti,ab,ot,kf,kw.
                                                                             2881687
164
        28
                 exp Critical Care/67547
165
        29
                 exp Intensive Care Units/ 107853
166
                 (close attention unit$ or intensive care or respiratory care unit or respiratory care units or special care
        30
167
        unit or special care units or high dependency unit or high dependency units).ti,ab,ot,kf,kw.
168
        31
                 (ICU or ICUs or CCU or CCus or GICU or GICUs or HDU or HDUs or ITU or ITUs).ti,ab,ot,kf,kw.
169
                 95415
170
        32
                 (Hospitaliz$ or Hospitalis$ or (hospital adi2 Admission$) or Critical Care).ti,ab,ot,kf,kw. 436800
171
        33
                 Hospitalization/ 137866
172
                 ("length of stay" or "duration of stay" or "extended stay" or "prolonged stay" or "hospital
        34
173
        stay").ti,ab,ot,hw. 220112
174
                 "Length of Stay"/103573
        35
175
176
                 ("in-patient stay" or "inpatient stay" or "in-patient stays" or "inpatient stays").ti,ab,ot,hw. 3851
        36
        37
                 or/25-363560422
177
        38
                 exp risk/1397708
178
        39
                 odds ratio/ or proportional hazards models/ 185114
179
        40
                 life tables/
180
        41
                 (risk$ or danger$ or association$ or peril or jeopard$ or threat$ or chance or chances or hazard$ or
181
        gamble$ or probabilit$ or "at stake" or endanger$ or associat$ or likelihood$ or possibilit$ or correlation$ or
182
        odds).ti,ab,ot,kf,kw.
                                  9312430
183
        42
                 (morbidit$ or comorbid$ or co-morbid$).ti,ab,ot,kf,kw.
                                                                             716968
184
                                                                                      3993128
        43
                 (incidence or prevalence or predict$ or prognosis).ti,ab,ot,kf,kw.
185
        44
                 (HR or RR or aiRR or aOR or "adjusted OR").ti,ab,ot,kf,kw. 471257
186
        45
                 or/38-44 11628532
187
                 Epidemiologic studies/
                                           9457
        46
188
                 exp case control studies/
        47
                                          1470108
189
        48
                 exp cohort studies/
                                           2556574
190
        49
                 Case control.tw. 158730
191
        50
                 Longitudinal.tw. 335439
192
        51
                 Retrospective.tw. 782068
193
        52
                 Cross sectional.tw.
                                           540774
194
        53
                 Cross-sectional studies/
                                           487981
```

- Observational Studies as Topic/ (observational adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. 234202 ((follow up or followup) adj7 (study or studies or design or analysis or analyses)).ti,ab,kf. 175238 (epidemiologic\$ adj3 (study or studies or design or analysis or analyses)).ti,ab.kf. ((longterm or (long adj term)) adj7 (study or studies or design or analysis or analyses or data)).ti,ab,kf. (cohort\$ adj3 (study or studies or design or analysis or analyses or data)).ti,ab,kf. (prospective adj7 (study or studies or design or analysis or analyses)).ti,ab,kf. or/46-604243864 animals/ not (animals/ and humans/) 61 not 62 63 not (case reports or clinical conference or comment or editorial or letter).pt. 3929840 limit 64 to yr="2022 -Current" 24 and 37 and 45 and 65 3385
  - The Medline ALL strategy was updated on 1.2.24 (363 records) and 1.3.24 (363 records).

COVID facet based on terms from:

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from: <a href="https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5">https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5</a>

Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-19 — EMBASE (Internet). Available from: <a href="https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/">https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/</a>

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: <a href="https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445">https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445</a>

Observational study design filter adapted from:

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Medline. Edinburgh: SIGN, Last Modified 24/04/17 Available from: <a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters/">https://www.sign.ac.uk/what-we-do/methodology/search-filters/</a>

Observational Studies - Medline. In: CADTH Search Filters Database. Ottawa: CADTH; 2023 [accessed 7.11.23]:

 $\underline{https://searchfilters.cadth.ca/list?q=topic\%3A\%22Observational\%20studies\%22\&p=1\&ps=\&sort=title\_sort\%20asc$ 

PubMed (NLM): 2022-2024/01/03 Searched 3.1.24

https://pubmed.ncbi.nlm.nih.gov/

- 35 #13 AND #30 AND #34 AND #24 AND #25 1,047
  34 #31 OR #32 OR #33 9,159,936
  33 morbidity[Title/Abstract] OR comorbidity[Title/Abstract] OR "co-morbidities"[Title/Abstract] OR morbidities[Title/Abstract] OR comorbidities[Title/Abstract] OR "co-morbidities"[Title/Abstract] OR incidence[Title/Abstract] OR prevalence[Title/Abstract] OR predict[Title/Abstract] OR predicted[Title/Abstract] OR predictive[Title/Abstract] OR prognosis[Title/Abstract] OR prediction[Title/Abstract] OR predictions[Title/Abstract] OR HR[Title/Abstract] OR RR[Title/Abstract] OR aiRR[Title/Abstract] OR aoR[Title/Abstract] OR "adjusted OR"[Title/Abstract] OR danger[Title/Abstract] OR danger[T
- risk[Title/Abstract] OR risks[Title/Abstract] OR risky[Title/Abstract] OR danger[Title/Abstract] OR dangers[Title/Abstract] OR dangerous[Title/Abstract] OR association[Title/Abstract] OR peril[Title/Abstract] OR jeopardy[Title/Abstract] OR jeopardise[Title/Abstract]

```
253
        OR jeopardize[Title/Abstract] OR threat[Title/Abstract] OR threats[Title/Abstract] OR chance[Title/Abstract]
254
        OR chances[Title/Abstract] OR hazard[Title/Abstract] OR hazards[Title/Abstract] OR hazards[Title/Abstract]
255
        OR gamble[Title/Abstract] OR gambles[Title/Abstract] OR gambling[Title/Abstract] OR
256
        probability[Title/Abstract] OR probabilities[Title/Abstract] OR "at stake"[Title/Abstract] OR
257
        endanger[Title/Abstract] OR endangers[Title/Abstract] OR endangered[Title/Abstract] OR
258
        endangering[Title/Abstract] OR associate[Title/Abstract] OR associates[Title/Abstract] OR
259
        associating[Title/Abstract] OR association[Title/Abstract] OR likelihood[Title/Abstract] OR
260
        likelihoods[Title/Abstract] OR possibility[Title/Abstract] OR possibilities[Title/Abstract] OR
261
        correlation[Title/Abstract] OR correlations[Title/Abstract] OR odds[Title/Abstract]
262
                 ((("Risk"[Mesh]) OR "Odds Ratio"[Mesh:NoExp]) OR "Proportional Hazards Models"[Mesh:NoExp])
263
        OR "Life Tables" [Mesh:NoExp]
                                           1,481,626
264
        30
                 #26 OR #27 OR #28 OR #29
                                                   3,581,605
265
        29
                 Hospitalized[Title/Abstract] OR Hospitalised population[Title/Abstract] OR
266
        Hospitalization[Title/Abstract] OR Hospitalisation[Title/Abstract] OR Hospitalizations[Title/Abstract] OR
267
        Hospitalisations[Title/Abstract] OR "hospital Admission"[Title/Abstract] OR "hospital
268
        Admissions"[Title/Abstract] OR "Critical Care"[Title/Abstract] OR "length of stay"[Title/Abstract] OR
269
         "duration of stay"[Title/Abstract] OR "extended stay"[Title/Abstract] OR "prolonged stay"[Title/Abstract] OR
270
         "hospital stay"[Title/Abstract] OR "in-patient stay"[Title/Abstract] OR "inpatient stay"[Title/Abstract] OR "in-
271
        patient stays"[Title/Abstract] OR "inpatient stays"[Title/Abstract]
                                                                             565,867
272
                 mortality[Title/Abstract] OR death[Title/Abstract] OR deaths[Title/Abstract] OR fatal[Title/Abstract]
        28
273
        OR fatality[Title/Abstract] OR fatalities[Title/Abstract] OR survival[Title/Abstract] OR "close attention
274
        unit"[Title/Abstract] OR "close attention units"[Title/Abstract] OR "intensive care"[Title/Abstract] OR
275
         "respiratory care unit" [Title/Abstract] OR "respiratory care units" [Title/Abstract] OR "special care
276
277
        unit"[Title/Abstract] OR "special care units"[Title/Abstract] OR "high dependency unit"[Title/Abstract] OR
         "high dependency units" [Title/Abstract] OR ICU [Title/Abstract] OR ICUs [Title/Abstract] OR
278
        CCU[Title/Abstract] OR CCus[Title/Abstract] OR GICU[Title/Abstract] OR GICUs[Title/Abstract] OR
279
        HDU[Title/Abstract] OR HDUs[Title/Abstract] OR ITU[Title/Abstract] OR ITUs[Title/Abstract] 3,013,975
280
                 ((("Length of Stay"[Mesh:NoExp]) OR "Critical Care"[Mesh]) OR "Intensive Care Units"[Mesh]) OR
        27
281
        "Hospitalization" [Mesh] 429,629
282
                 ((((("Mortality"[Mesh:NoExp]) OR "Cause of Death"[Mesh:NoExp]) OR "Fatal
283
        Outcome" [Mesh:NoExp]) OR "Hospital Mortality" [Mesh:NoExp]) OR "Survival Rate" [Mesh:NoExp]) OR
284
        "Death"[Mesh:NoExp]
                                  408,041
285
        25
                 pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]
                                                                                     5,627,356
286
        24
                 #22 AND #23
                                  493,476
287
        23
                 ("2022/01/01"[Date - Publication] : "3000"[Date - Publication])
                                                                                     3,253,097
288
        22
                 #20 NOT #21
                                  3,739,291
289
        21
                 LETTER[Publication Type] OR EDITORIAL[Publication Type] OR COMMENT[Publication Type]
290
                 2,213,615
291
        20
                                  3,825,199
                 #16 NOT #19
292
        19
                 #18 NOT (#18 AND #17) 3,757,858
293
        18
                 rat[tiab] or rats[tiab] or mouse[tiab] or mice[tiab] or murine[tiab] or rodent[tiab] or rodents[tiab] or
294
        hamster[tiab] or hamsters[tiab] or pig[tiab] or pigs[tiab] or porcine[tiab] or rabbits[tiab] or rabbits[tiab] or
295
        animal[tiab] or animals[tiab] or dogs[tiab] or cats[tiab] or cow[tiab] or bovine[tiab] or sheep[tiab]
296
        or ovine[tiab] or monkey[tiab] or monkeys[tiab]
                                                           4,715,684
297
                 Human*[tiab]
        17
                                  3,295,660
298
                 #14 OR #15
        16
                                  3.914.514
299
                 ((("Epidemiologic Studies"[Mesh:NoExp]) OR "Case-Control Studies"[Mesh]) OR "Cohort
        15
300
        Studies" [Mesh]) OR "Cross-Sectional Studies" [Mesh:NoExp] 3,195,884
301
                  'Case control"[Title/Abstract] OR "cohort study"[Title/Abstract] OR "cohort studies"[Title/Abstract]
302
        OR "cohort analysis" [Title/Abstract] OR "cohort analyses" [Title/Abstract] OR "follow up study" [Title/Abstract]
303
        OR "follow up studies" [Title/Abstract] OR "observational study" [Title/Abstract] OR "observational
304
        studies"[Title/Abstract] OR Longitudinal[Title/Abstract] OR Retrospective[Title/Abstract] OR "Cross
305
        sectional"[Title/Abstract] 2,068,573
306
        13
                 #9 OR #11 OR #12
                                           47,832
307
                 omikron[Title/Abstract] OR Omicron[Title/Abstract] OR "B.1.1.529"[Title/Abstract] OR
        12
308
        "B11529"[Title/Abstract] OR xbb[Title/Abstract]
                                                            9,468
309
        11
                 #7 AND #10
                                  31.553
```

- 310 strain[Title/Abstract] OR strains[Title/Abstract] OR variant[Title/Abstract] OR variants[Title/Abstract] 311 OR mutation[Title/Abstract] OR mutations[Title/Abstract] 1,893,774 312 #7 AND #8 17,832 313 8 "2022"[Title/Abstract] OR "2023"[Title/Abstract] 158,464 314 7 #1 OR #4 OR #5 OR #6 412,676 315 "COVID-19 2019"[Title/Abstract] OR ncov[Title/Abstract] OR "sars cov"[Title/Abstract] OR 316 sarscov[Title/Abstract] OR "sars coronavirus" [Title/Abstract] OR coronovirus [Title/Abstract] OR "corono 317 virus"[Title/Abstract] OR "19-nCoV"[Title/Abstract] OR "19nCoV"[Title/Abstract] OR 318 "SARS2"[Title/Abstract] OR "SARS-2"[Title/Abstract] OR SARScoronavirus[Title/Abstract] OR "SARS-319 coronavirus"[Title/Abstract] OR SARScoronovirus[Title/Abstract] OR "SARS-coronovirus"[Title/Abstract] OR 320 "HCoV-19"[Title/Abstract] OR "HCoV19"[Title/Abstract] OR "HCoV-2019"[Title/Abstract] OR 321 "HCoV2019"[Title/Abstract] OR "2019 novel"[Title/Abstract] OR "Severe Acute Respiratory Syndrome 322 Coronavirus 2"[Title/Abstract] OR "Severe Acute Respiratory Syndrome Corona Virus 2"[Title/Abstract] 323 141.123 324 "Coronavirus"[Title/Abstract] OR "covid 19"[Title/Abstract] OR "2019-ncov"[Title/Abstract] OR 325 "2019-ncov"[Title/Abstract] OR "2019ncov"[Title/Abstract] OR "corona-virus"[Title/Abstract] OR 326 "cov19"[Title/Abstract] OR "cov-19"[Title/Abstract] OR "19nCoV"[Title/Abstract] OR 327 328 "COVID19"[Title/Abstract] OR "COVID2019"[Title/Abstract] #2 AND #3 83,020 329 (("Epidemics"[Mesh:NoExp]) OR "Pandemics"[Mesh:NoExp]) OR "Disease 3 330 331 Outbreaks" [Mesh: NoExp] 226,548 ((("Coronaviridae" [Mesh:NoExp]) OR "Coronavirus" [Mesh]) OR "Betacoronavirus" [Mesh:NoExp]) 332 OR "Coronavirus Infections" [Mesh:NoExp] 185,366 333 334
  - The PubMed strategy was updated on 1.2.24 (92 records) and 1.3.24 (68 records).

COVID facet based on terms from:

258,558

335 336

337 338

339 340

341

342

343

344

345 346

347

348

349 350

351

352

353 354 355

356

357

358 359

360

361

362

363 364

365

366

367

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from: https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19 sources searchstrategy 20210526.pdf?sfvrsn=65209cc2 5

("COVID-19"[Mesh]) OR "Severe acute respiratory syndrome-related coronavirus"[Mesh]

Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-19 — EMBASE (Internet). Available from: https://covid.cadth.ca/literature-searching-tools/cadth-covid-19search-strings/

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445

Observational study design filter adapted from:

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Medline. Edinburgh: SIGN, Last Modified 24/04/17 Available from: https://www.sign.ac.uk/what-we-do/methodology/search-filters/

PubMed limit:

Duffy S, de Kock S, Misso K, Noake C, Ross J, Stirk L. Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via Ovid. J Med Libr Assoc. 2016 Oct;104(4):309-312. doi: 10.3163/1536-5050.104.4.011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079494/

Europe PMC, including medRxiv and bioRxiv preprints (Internet): up to 2024/01/04 Searched 4.1.24

https://europepmc.org/

Search terms	Results
(TITLE:"COVID-19" OR TITLE:"coronavirus" OR TITLE:"COVID" OR TITLE:"NCOV" OR TITLE:"SARS-CoV-2") AND (TITLE:"risk" OR TITLE:"risks" OR TITLE:"hazard" OR TITLE:"hazards" OR TITLE:"probability" OR TITLE:"probabilities" OR TITLE:"likelihood" OR TITLE:"morbidity" OR TITLE:"comorbidity" OR TITLE:"predict" OR TITLE:"predictive" OR TITLE:"HR" OR TITLE:"RR" OR TITLE:"aiRR" OR TITLE:"aOR" OR TITLE:"adjusted OR") AND (TITLE:"2022" OR TITLE:"2023" OR TITLE:"strain" OR TITLE:"strains" OR TITLE:"variant" OR TITLE:"variants" OR TITLE:"mutation" OR TITLE:"mutations" OR TITLE:"omicron")	89

The Europe PMC strategy was updated on 1.2.24 (0 records) and 1.3.24 (3 records).

Latin American and Caribbean Health Sciences Literature (LILACS) (Internet): 2022-2024/01/07 Searched 4.1.24

https://search.bvsalud.org/portal/?lang=en

Searched Title/Abstract/Subject Limited to Observational studies Limited to 2022-2024/01/04 Limited to LILACS only

((COVID OR NCOV OR coronavirus OR COVID19 OR "SARs-COV-2" OR Omicron OR omicron)) AND ((mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care unit" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUs OR HDU OR HDUs OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalisations OR "hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stay" OR "inpatient stays" OR "inpatient stays") ) AND ((risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazardous OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR associating OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR aiRR OR aOR OR "adjusted OR")) AND ((2022 OR 2023 OR 2024 OR strain OR strains OR variant OR variants OR mutations OR mutation OR omikron OR Omicron OR "B.1.1.529" OR "B11529" OR xbb))

N=38

368 369

370 371

372

373

374 375

376

377

378

379 380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398 399

400 401

402 403

404

405

406 407

408

409

The LILACS strategy was updated on 1.2.24 (3 records) and 1.3.24 (0 records).

Cochrane COVID-19 Study Register (www): 2022-2024/01/04 Searched 4.1.24

https://covid-19.cochrane.org/

Limited to Observational cohort studies. Limited 2022-2024/01/04

(mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care unit" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUs OR HDU OR HDUs OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalisations OR "hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stay" OR "inpatient stays" OR "inpatient stays") AND (risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazardous OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR associating OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR aiRR OR aOR OR "adjusted OR") AND (2022 OR 2023 OR 2024 OR strain OR strains OR variants OR mutations OR mutation OR omikron OR Omicron OR "B.1.1.529" OR "B11529" OR xbb) AND (cohort OR cohorts OR observational OR "follow up" OR followup OR epidemiologic OR epidemiological OR longterm OR "long term" OR longitudinal OR prospective)

### N=3814

The Cochrane COVID-19 Study Register strategy was updated on 1.2.24 (0 records) and 1.3.24 (59 records).

WHO COVID-19 (Internet): 2022-2024/01/03

Searched 3.1.24

https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/?lang=en

### Advanced search (title only)

(ti:(mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUs OR HDU OR HDUs OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalizations OR Hospitalisations OR "hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stays" OR "inpatient stays")) AND (ti:(risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazardous OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR airR OR aOR OR "adjusted OR"))

Limited to Observational and cohort studies.

Limited 2022-2023/06.

### N=2268

\* WHO COVID-19 database ceased on June 2023, therefore update searches were not necessary.

## Search 2: Protective effect of vaccination on burden/risk of COVID-19 infection search strategies

```
464
465
        Embase (Ovid): 2022-2023/12/29
466
        Searched 2.1.24
467
468
        1
                 exp coronavirus disease 2019/
                                                  374674
469
                 sars-related coronavirus/ or exp Severe acute respiratory syndrome coronavirus 2/
                                                                                                     106902
        2
470
        3
                 (coronavirinae/ or betacoronavirus/ or coronavirus infection/) and (epidemic/ or pandemic/)
471
                 10615
472
                 (Coronavirus$ or "covid 19" or 2019-ncov).ti,ab,kw,kf,ot.
                                                                            430070
        4
473
        5
                 (2019-ncov or 2019ncov or corona-virus$ or cov19 or cov-19 or 19nCoV or COVID19 or COVID2019
474
        or "COVID-19 2019").ti,ab,kw,kf,ot.
                                                   15833
475
                 (ncov$ or "sars cov$" or sarscov$ or "sars coronavirus$" or coronovirus$ or corono$ virus$ or "19-
476
        nCoV$" or 19nCoV$).ti.ab.kw.kf.ot.
                                                   160670
477
                 (SARS2$ or "SARS-2$" or SARScoronavirus$ or SARS-coronavirus$ or SARScoronovirus$ or
478
        SARS-coronovirus$).ti,ab,kw,kf,ot. 2922
479
                 ("HCoV-19$" or HCoV19$ or "HCoV-2019$" or HCoV2019$).ti,ab,kw,kf,ot.
480
        9
                 ("2019 novel$" or Ncov$).ti,ab,kw,kf,ot.
                                                           5843
481
        10
                 ("Severe Acute Respiratory Syndrome Coronavirus 2" or "Severe Acute Respiratory Syndrome Corona
482
        Virus 2").ti,ab,kw,kf,ot.
                                 36797
483
                 or/1-10 496535
        11
484
                 ("2022" or "2023").ti,ab,ot.
        12
                                                  235450
485
        13
                 11 and 12
                                  26927
486
        14
                 (strain or strains or variant$ or mutation$).ti,ab,ot,kf,kw.
                                                                            2383716
487
        15
                 11 and 14
                                  36992
488
        16
                 exp "SARS-CoV-2 (lineage B.1.1)"/
                                                           8191
489
        17
                 exp "SARS-CoV-2 Omicron"/
                                                  7250
490
        18
                 (omikron or Omicron or "B.1.1.529" or "B11529" or xbb$).af. 13566
491
        19
                 or/16-18 14551
492
        20
                 or/13,15,19
                                  63058
493
        21
                 Clinical study/
                                  165138
494
        22
                 Case control study/
                                          211296
495
        23
                 Family study/
                                  25764
496
        24
                 Longitudinal study/
                                          203445
497
        25
                 Retrospective study/
                                          1544157
498
                 Prospective study/
        26
                                          899644
499
        27
                 Randomized controlled trials/
                                                  267337
500
        28
                 26 not 27
                                  888668
501
                 Cohort analysis/ 1096585
        29
502
        30
                 (Cohort adj (study or studies)).mp. 493516
503
                 (Case control adj (study or studies)).tw.
        31
                                                           171865
504
                 (follow up adj (study or studies)).tw.
        32
                                                           74874
505
        33
                 (observational adj (study or studies)).tw.
                                                           264634
506
        34
                 (epidemiologic$ adj (study or studies)).tw.
                                                           123898
507
        35
                 (cross sectional adj (study or studies)).tw.
                                                           356386
508
        36
                 or/21-25,28-35
                                 4072059
509
        37
                 animal/ or animal experiment/
                                                  4720382
510
        38
                 (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
511
        porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or ovine or
512
        monkey or monkeys).ti,ab,ot,hw. 7724982
513
                 or/37-387724982
        39
514
        40
                 human experiment/ or exp humans/ 25973725
515
                 39 not (39 and 40)
        41
                                          5781960
516
        42
                 36 not 41
                                  4009600
517
                 limit 42 to vr="2022 -Current"
        43
                                                  754329
518
        44
                 43 not (letter or editorial or conference or "conference abstract" or "conference paper" or "conference
519
        review").pt.
                         555478
520
                 mortality/ or death/ or "cause of death"/ or survival rate/
        45
                                                                            1478645
```

```
521
        46
                 (mortalit$ or death$ or fatal$ or survival).ti,ab,ot,kf,kw.
                                                                             4124730
522
        47
                 exp intensive care/ or exp intensive care unit/ or high dependency unit/ 1066416
523
        48
                 (close attention unit$ or intensive care or respiratory care unit or respiratory care units or special care
524
        unit or special care units or high dependency unit or high dependency units).ti,ab,ot,kf,kw.
525
                 (ICU or ICUs or CCU or CCus or GICU or GICUs or HDU or HDUs or ITU or ITUs).ti,ab,ot,kf,kw.
526
527
        50
                 (Hospitaliz$ or Hospitalis$ or (hospital adj2 Admission$) or Critical Care).ti,ab,ot,kf,kw. 716741
528
        51
                 hospitalization/ 546684
529
        52
                 ("length of stay" or "duration of stay" or "extended stay" or "prolonged stay" or "hospital
530
        stay").ti,ab,ot,hw.412206
531
                 ("in-patient stay" or "inpatient stay" or "in-patient stays" or "inpatient stays").ti,ab,ot,hw. 7835
        53
532
        54
                 exp risk/ or exp risk factor/ or exp risk assessment/
533
        55
                 hazard ratio/ or odds ratio/99395
534
        56
                 mortality risk/
                                  46876
535
                 (risk$ or danger$ or association$ or peril or jeopard$ or threat$ or chance or chances or hazard$ or
        57
536
        gamble$ or probabilit$ or "at stake" or endanger$ or associat$ or likelihood$ or possibilit$ or correlation$ or
537
        odds or "vaccine effectiveness" or "immune evasion" or "immunity evasion").ti,ab,ot,kf,kw.
                                                                                                       12518691
538
                 (morbidit$ or comorbid$ or co-morbid$).ti,ab,ot,kf,kw.
                                                                              1138678
        58
539
        59
                 (incidence or prevalence or predict$ or prognosis).ti,ab,ot,kf,kw.
                                                                                      5507851
540
        60
                 (HR or RR or aiRR or aOR or "adjusted OR").ti,ab,ot,kf,kw. 753007
541
                 disease severity assessment/ or covid-19 severity score/ or global severity index/ or quick covid-19
        61
542
        severity index/ or "severity of illness index"/32588
543
        62
                 morbidity/
544
        63
                 disease severity/ or critical illness/ or emergency status/ or urgency status/
                                                                                               772357
545
        64
                 ((severe or severity) adj3 (disease$ or infection$ or illness$ or complication$ or condition$ or
546
        illhealth$ or ill-health$ or sickness or virus or infirmity or affliction$)).ti,ab,ot,kf,kw.
                                                                                              423477
547
                 morbidit$.ti,ab,ot,kf,kw. 754095
        65
548
                 or/45-65 18057098
        66
549
        67
                 Tozinameran/
                                  11540
550
                 ((pfizer$ or biontech) adj5 vaccin$).ti,ab,ot,kf,kw,hw,du,dy,tn,rn.
        68
                                                                                      4443
551
                 (tozinameran or Comirnaty or "Pfizer-BioNTech" or "pf07302048" or "pf-07302048" or "BNT-162b2"
        69
552
        or "BNT162b2" or Pidacmeran or "BNT162C2" or "BNT-162C2" or Abdavomeran or "BNT-162B1" or
553
        "BNT162B1" or "BNT162A1" or "BNT-162A1").ti,ab,ot,kf,kw,hw,du,dy,tn,rn. 15132
554
        70
                 "Pfizer-BioNTech".mf.
                                           947
555
        71
                 "2417899-77-3".af.
                                           12357
556
        72
                 elasomeran/
557
        73
                 (Elasomeran or moderna or Spikevax or davesomeran or imelasomeran or andusomeran or "mRNA"
558
        1273" or "mRNA1273" or "mRNA-1273.211" or "mRNA 1273.211" or Spikevax or "M-1273" or "M1273" or
559
         "CX-024414" or "CX024414" or "TAK-919" or "TAK919").ti,ab,ot,kf,kw,hw,du,dy,tn,rn.
                                                                                                       9771
560
                 ("2430046-03-8" or "2457298-05-2").af.
        74
                                                            6468
561
        75
                 RNA vaccine/
                                  5844
562
                 (("messenger RNA" or mrna or "RNA based") adj4 (vaccin$ or jab or jabs or shot or shots or immunis$
        76
563
        or immuniz$)).ti,ab,ot,kf,kw.
                                           12887
564
                 or/67-7625983
565
        78
                 and/20,44,66,77 1628
566
```

The Embase strategy was updated on 1.2.24 (110 records) and 1.3.24 (86 records).

COVID facet based on terms from:

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from: <a href="https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5">https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-sources-searchstrategy-20210526.pdf?sfvrsn=65209cc2-5</a>

577 Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-578 19 — EMBASE (Internet). Available from: <a href="https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/">https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/</a>

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445

Observational study design filter adapted from:

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Embase. Edinburgh: SIGN, Last Modified 24/04/17 Available from: <a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters/">https://www.sign.ac.uk/what-we-do/methodology/search-filters/</a>

Observational Studies - Embase. In: CADTH Search Filters Database. Ottawa: CADTH; 2023 [accessed 7.11.23]: <a href="https://searchfilters.cadth.ca/link/37">https://searchfilters.cadth.ca/link/37</a>

## Medline ALL (Ovid): 2022-2024/01/02 Searched 2.1.24

596 1 exp COVID-19/ 250794
597 2 exp Severe acute respirator

- 2 exp Severe acute respiratory syndrome-related coronavirus/ 166686
- 598 3 coronaviridae/ or exp coronavirus/ 178833
- 599 4 Betacoronavirus/ 33277
- 600 5 Coronavirus Infections/ 46094
- 601 6 or/3-5 185838

581

582

583

584 585

586 587

588

589 590

591

592 593

594

595

- 602 7 epidemics/ or pandemics/ 139078
- 603 8 Disease Outbreaks/ 92374
- 604 9 or/7-8 226884
- 605 10 6 and 9 83151
- 606 11 (Coronavirus\$ or "covid 19" or 2019-ncov).ti,ab,kw,kf,ot. 385791
- 607 12 (2019-ncov or 2019ncov or corona-virus\$ or cov19 or cov-19 or 19nCoV or COVID19 or COVID2019
- 608 or "COVID-19 2019").ti,ab,kw,kf,ot. 10202
- 609 13 (ncov\$ or "sars cov\$" or sarscov\$ or "sars coronavirus\$" or coronovirus\$ or corono\$ virus\$ or "19-
- 610 nCoV\$" or 19nCoV\$).ti,ab,kw,kf,ot. 140222
- 611 14 (SARS2\$ or "SARS-2\$" or SARScoronavirus\$ or SARS-coronavirus\$ or SARScoronovirus\$ or
- SARS-coronovirus\$).ti,ab,kw,kf,ot.2635
- 613 15 ("HCoV-19\$" or HCoV19\$ or "HCoV-2019\$" or HCoV2019\$).ti,ab.kw,kf,ot. 66
- 614 16 ("2019 novel\$" or Ncov\$).ti,ab,kw,kf,ot. 5236
- 615 17 ("Severe Acute Respiratory Syndrome Coronavirus 2" or "Severe Acute Respiratory Syndrome Corona
- 616 Virus 2").ti,ab,kw,kf,ot. 36907
- **617** 18 or/1-2,10-17 416995
- 618 19 ("2022" or "2023").ti,ab,ot. 153808
- **619** 20 18 and 19 17876
- 620 21 (strain or strains or variant\$ or mutation\$).ti,ab,ot,kf,kw. 1916135
- **621** 22 18 and 21 32095
- 622 23 (omikron or Omicron or "B.1.1.529" or "B11529" or xbb\$).af. 9846
- **623** 24 or/20,22-23 48695
- **624** 25 Epidemiologic studies/ 9457
- 625 26 exp case control studies/ 1470108
- 626 27 exp cohort studies/ 2556574
- 627 28 Case control.tw. 158730
- **628** 29 Longitudinal.tw. 335439
- 629 30 Retrospective.tw. 782068
- 630 31 Cross sectional.tw. 540774
- 631 32 Cross-sectional studies/ 487981
- 632 33 Observational Studies as Topic/ 9294
- 633 34 (observational adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. 234202
- 634 35 ((follow up or followup) adj7 (study or studies or design or analysis or analyses)).ti,ab,kf. 175238

```
635
        36
                 (epidemiologic$ adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
                                                                                                        119921
636
        37
                 ((longterm or (long adj term)) adj7 (study or studies or design or analysis or analyses or data)).ti,ab,kf.
637
                 160631
638
        38
                 (cohort$ adj3 (study or studies or design or analysis or analyses or data)).ti,ab,kf.
                                                                                                        420054
639
                 (prospective adj7 (study or studies or design or analysis or analyses)).ti,ab,kf.
        39
640
        40
                 or/25-39 4243864
641
        41
                 animals/ not (animals/ and humans/)
                                                            5148855
642
        42
                 40 not 41
                                  4139882
643
        43
                 42 not (case reports or clinical conference or comment or editorial or letter).pt. 3929840
644
        44
                 limit 43 to yr="2022 -Current"
                                                    538850
645
        45
                 mortality/ or "cause of death"/ or fatal outcome/ or hospital mortality/ or survival rate/ or Death/
646
                 408166
647
        46
                 (mortalit$ or death$ or fatal$ or survival).ti,ab,ot,kf,kw.
                                                                              2881687
648
        47
                 exp Critical Care/ or exp Intensive Care Units/
                                                                     159166
649
        48
                 (close attention unit$ or intensive care or respiratory care unit or respiratory care units or special care
650
        unit or special care units or high dependency unit or high dependency units).ti,ab,ot,kf,kw.
651
                 (ICU or ICUs or CCU or CCus or GICU or GICUs or HDU or HDUs or ITU or ITUs).ti,ab,ot,kf,kw.
        49
652
                 95415
653
        50
                 (Hospitaliz$ or Hospitalis$ or (hospital adj2 Admission$) or Critical Care).ti,ab,ot,kf,kw. 436800
654
        51
                 Hospitalization/ or "Length of Stay"/
                                                             228750
655
                 ("length of stay" or "duration of stay" or "extended stay" or "prolonged stay" or "hospital
        52
656
        stay").ti,ab,ot,hw. 220112
657
        53
                 ("in-patient stay" or "inpatient stay" or "in-patient stays" or "inpatient stays").ti,ab,ot,hw. 3851
658
        54
                 exp risk/ or odds ratio/ or proportional hazards models/ or life tables/
659
        55
                 (risk$ or danger$ or association$ or peril or jeopard$ or threat$ or chance or chances or hazard$ or
660
        gamble$ or probabilit$ or "at stake" or endanger$ or associat$ or likelihood$ or possibilit$ or correlation$ or
661
        odds or "vaccine effectiveness" or "immune evasion" or "immunity evasion").ti,ab,ot,kf,kw.
                                                                                                        9321739
662
                 (morbidit$ or comorbid$ or co-morbid$).ti,ab,ot,kf,kw.
                                                                              716968
        56
663
        57
                 (incidence or prevalence or predict$ or prognosis).ti,ab,ot,kf,kw.
                                                                                      3993128
664
                 (HR or RR or aiRR or aOR or "adjusted OR").ti,ab,ot,kf,kw. 471257
        58
665
        59
                 "severity of illness index"/ or sickness impact profile/277780
666
        60
                 patient acuity/ or early warning score/
                                                             3345
667
        61
                 Morbidity/
                                   34586
668
        62
                 Critical Illness/
                                  39796
669
        63
                 Emergencies/
                                  43459
670
                 ((severe or severity) adj3 (disease$ or infection$ or illness$ or complication$ or condition$ or
        64
671
        illhealth$ or ill-health$ or sickness or virus or infirmity or affliction$)).ti,ab,ot,kf,kw.
672
                 or/45-64 13120377
        65
673
        66
                 exp mRNA Vaccines/
                                           5326
674
                 ((pfizer$ or biontech) adj5 vaccin$).ti,ab,ot,kf,kw,hw,nm,rn. 3046
        67
675
                 (tozinameran or Comirnaty or "Pfizer-BioNTech" or "pf07302048" or "pf-07302048" or "BNT-162b2"
676
        or "BNT162b2" or Pidacmeran or "BNT162C2" or "BNT-162C2" or Abdavomeran or "BNT-162B1" or
677
        "BNT162B1" or "BNT162A1" or "BNT-162A1").ti,ab,ot,kf,kw,hw,nm,rn.
                                                                                      6421
678
        69
                 "Pfizer-BioNTech".af.
                                           2384
679
        70
                 "2417899-77-3".af.
680
                 (Elasomeran or moderna or Spikevax or davesomeran or imelasomeran or andusomeran or "mRNA"
        71
681
        1273" or "mRNA1273" or "mRNA-1273.211" or "mRNA 1273.211" or Spikevax or "M-1273" or "M1273" or
682
         "CX-024414" or "CX024414" or "TAK-919" or "TAK919").ti,ab,ot,kf,kw,hw,nm,rn.
683
        72
                 ("2430046-03-8" or "2457298-05-2").af.
684
        73
                 (("messenger RNA" or mrna or "RNA based") adj4 (vaccin$ or jab or jabs or shot or shots or immunis$
685
        or immuniz$)).ti,ab,ot,kf,kw.
                                           10148
686
                 or/66-73 15059
        74
687
        75
                 24 and 44 and 74 and 65 825
688
```

The Medline ALL strategy was updated on 1.2.24 (51 records) and 1.3.24 (63 records).

COVID facet based on terms from:

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from:

<a href="https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-

Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-19 — EMBASE (Internet). Available from: <a href="https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/">https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/</a>

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445

Observational study design filter adapted from:

698 699

700

701

702 703

704

705

706 707

708 709

710

711

712 713

714

715

716

717 718

719 720

721 722

723

724

725

726

727

728

729

730

731

732

733

Observational study design filter adapted from:

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Medline. Edinburgh: SIGN, Last Modified 24/04/17 Available from: <a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters/">https://www.sign.ac.uk/what-we-do/methodology/search-filters/</a>

Observational Studies - Medline. In: CADTH Search Filters Database. Ottawa: CADTH; 2023 [accessed 7.11.23]:

 $\underline{https://searchfilters.cadth.ca/list?q=topic\%3A\%22Observational\%20studies\%22\&p=1\&ps=\&sort=title\_sort\%20\\ \underline{asc}$ 

PubMed (NLM): 2022-2024/01/03 Searched 3.1.24

https://pubmed.ncbi.nlm.nih.gov/

- 32 #13 AND #24 AND #31 AND #25 281
- 31 #26 OR #27 OR #28 OR #29 OR #30 19,625
- 30 (("messenger RNA"[Title/Abstract] OR mrna[Title/Abstract] OR "RNA based"[Title/Abstract]) AND (vaccine[Title/Abstract] OR vaccines[Title/Abstract] OR vaccination[Title/Abstract] OR jabs[Title/Abstract] OR shots[Title/Abstract] OR shots[Title/Abstract] OR immunise[Title/Abstract] OR immunised[Title/Abstract] OR immunized[Title/Abstract] OR immunized[Title/Abstract] OR immunized[Title/Abstract] OR immunization[Title/Abstract]) 15,979
- 29 Elasomeran[Title/Abstract] OR moderna[Title/Abstract] OR Spikevax[Title/Abstract] OR davesomeran[Title/Abstract] OR imelasomeran[Title/Abstract] OR andusomeran[Title/Abstract] OR "mRNA 1273"[Title/Abstract] OR "mRNA1273"[Title/Abstract] OR "mRNA-1273.211"[Title/Abstract] OR "mRNA 1273.211"[Title/Abstract] OR Spikevax[Title/Abstract] OR "M-1273"[Title/Abstract] OR "M1273"[Title/Abstract] OR "CX-024414"[Title/Abstract] OR "CX024414"[Title/Abstract] OR "TAK-
- 734 919"[Title/Abstract] OR "TAK919"[Title/Abstract] OR "2430046-03-8"[Title/Abstract] OR "2457298-05-2"[Title/Abstract] 3,072
- 736 28 tozinameran[Title/Abstract] OR Comirnaty[Title/Abstract] OR "Pfizer-BioNTech"[Title/Abstract] OR
   737 "pf07302048"[Title/Abstract] OR "pf-07302048"[Title/Abstract] OR "BNT-162b2"[Title/Abstract] OR
   738 "BNT162b2"[Title/Abstract] OR Pidacmeran[Title/Abstract] OR "BNT-162b2"[Title/Abstract] OR "BN
- 739 162C2"[Title/Abstract] OR Abdavomeran[Title/Abstract] OR "BNT-162B1"[Title/Abstract] OR
- "BNT162B1"[Title/Abstract] OR "BNT162A1"[Title/Abstract] OR "BNT-162A1"[Title/Abstract] OR "Pfizer BioNTech"[Title/Abstract] OR "2417899-77-3"[Title/Abstract] 6,392
- 742 27 ((pfizer[Title/Abstract] OR biontech[Title/Abstract]) AND (vaccine[Title/Abstract] OR vaccines[Title/Abstract])) 3,668
- 744 26 "mRNA Vaccines" [Mesh] 5,307
- pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb] 5,627,356
- **746** 24 #22 AND #23 493,476
- 747 23 ("2022/01/01"[Date Publication]: "3000"[Date Publication]) 3,253,097
- **748** 22 #20 NOT #21 3,739,291
- 749 21 LETTER[Publication Type] OR EDITORIAL[Publication Type] OR COMMENT[Publication Type] 750 2,213,615

```
751
        20
                 #16 NOT #19
                                 3,825,199
752
        19
                 #18 NOT (#18 AND #17) 3,757,858
753
        18
                 rat[tiab] or rats[tiab] or mouse[tiab] or mice[tiab] or murine[tiab] or rodent[tiab] or rodents[tiab] or
754
        hamster[tiab] or hamsters[tiab] or pig[tiab] or pigs[tiab] or porcine[tiab] or rabbits[tiab] or rabbits[tiab] or
755
        animal[tiab] or animals[tiab] or dogs[tiab] or cats[tiab] or cow[tiab] or bovine[tiab] or sheep[tiab]
756
        or ovine[tiab] or monkey[tiab] or monkeys[tiab]
                                                           4,715,684
757
                 Human*[tiab]
                                 3,295,660
        17
758
                 #14 OR #15
                                 3,914,514
        16
759
                 ((("Epidemiologic Studies"[Mesh:NoExp]) OR "Case-Control Studies"[Mesh]) OR "Cohort
        15
760
        Studies"[Mesh]) OR "Cross-Sectional Studies"[Mesh:NoExp] 3,195,884
761
                 'Case control"[Title/Abstract] OR "cohort study"[Title/Abstract] OR "cohort studies"[Title/Abstract]
762
        OR "cohort analysis" [Title/Abstract] OR "cohort analysis" [Title/Abstract] OR "follow up study" [Title/Abstract]
763
        OR "follow up studies" [Title/Abstract] OR "observational study" [Title/Abstract] OR "observational
764
        studies"[Title/Abstract] OR Longitudinal[Title/Abstract] OR Retrospective[Title/Abstract] OR "Cross
765
        sectional"[Title/Abstract] 2.068.573
766
        13
                 #9 OR #11 OR #12
                                          47.832
767
        12
                 omikron[Title/Abstract] OR Omicron[Title/Abstract] OR "B.1.1.529"[Title/Abstract] OR
768
        "B11529"[Title/Abstract] OR xbb[Title/Abstract]
                                                           9,468
769
                 #7 AND #10
                                 31,553
        11
770
        10
                 strain[Title/Abstract] OR strains[Title/Abstract] OR variant[Title/Abstract] OR variants[Title/Abstract]
771
772
        OR mutation[Title/Abstract] OR mutations[Title/Abstract]
                                                                   1,893,774
                 #7 AND #8
                                  17,832
773
                 "2022"[Title/Abstract] OR "2023"[Title/Abstract]
        8
                                                                   158,464
774
        7
                 #1 OR #4 OR #5 OR #6 412,676
775
                 "COVID-19 2019"[Title/Abstract] OR ncov[Title/Abstract] OR "sars cov"[Title/Abstract] OR
776
        sarscov[Title/Abstract] OR "sars coronavirus"[Title/Abstract] OR coronovirus[Title/Abstract] OR "corono
777
        virus"[Title/Abstract] OR "19-nCoV"[Title/Abstract] OR "19nCoV"[Title/Abstract] OR
778
        "SARS2"[Title/Abstract] OR "SARS-2"[Title/Abstract] OR SARScoronavirus[Title/Abstract] OR "SARS-
779
        coronavirus"[Title/Abstract] OR SARScoronovirus[Title/Abstract] OR "SARS-coronovirus"[Title/Abstract] OR
780
        "HCoV-19"[Title/Abstract] OR "HCoV19"[Title/Abstract] OR "HCoV-2019"[Title/Abstract] OR
781
        "HCoV2019" [Title/Abstract] OR "2019 novel" [Title/Abstract] OR "Severe Acute Respiratory Syndrome
782
        Coronavirus 2"[Title/Abstract] OR "Severe Acute Respiratory Syndrome Corona Virus 2"[Title/Abstract]
783
784
                 "Coronavirus"[Title/Abstract] OR "covid 19"[Title/Abstract] OR "2019-ncov"[Title/Abstract] OR
785
        "2019-ncov"[Title/Abstract] OR "2019ncov"[Title/Abstract] OR "corona-virus"[Title/Abstract] OR
786
        "cov19"[Title/Abstract] OR "cov-19"[Title/Abstract] OR "19nCoV"[Title/Abstract] OR
787
        "COVID19"[Title/Abstract] OR "COVID2019"[Title/Abstract]
                                                                           382,642
788
        4
                 #2 AND #3
                                 83.020
789
                 (("Epidemics"[Mesh:NoExp]) OR "Pandemics"[Mesh:NoExp]) OR "Disease
790
        Outbreaks" [Mesh:NoExp] 226,548
791
                 ((("Coronaviridae"[Mesh:NoExp]) OR "Coronavirus"[Mesh]) OR "Betacoronavirus"[Mesh:NoExp])
792
        OR "Coronavirus Infections" [Mesh:NoExp] 185,366
793
                 ("COVID-19"[Mesh]) OR "Severe acute respiratory syndrome-related coronavirus"[Mesh]
794
```

### The PubMed strategy was updated on 1.2.24 (20 records) and 1.3.24 (17 records).

COVID facet based on terms from:

795 796

797 798

799 800

801

802

803

804

805 806

807

808

World Health Organization (26 May 2021) WHO COVID-19 Database Search Strategy. Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Available from: <a href="https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-sources/coronaviruse/who-covid-19-database/who-covid-19-sources/coronaviruse/who-covid-19-database/who-covid-19-sources/coronaviruse/who-covid-19-database/who-covid-19-sources/coronaviruse/who-covid-19-database/who-covid-19-sources/coronaviruse/who-covid-19-databas

Canadian Agency for Drugs and Technologies in Health (2.9.21) CADTH COVID-19 Search Strings: COVID-19 — EMBASE (Internet). Available from: <a href="https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/">https://covid.cadth.ca/literature-searching-tools/cadth-covid-19-search-strings/</a>

809 810

811 812

813

814 815 816

COVID-19 [NG188]. Search history record [PDF]. NICE: London. Available from: https://www.nice.org.uk/guidance/ng188/evidence/search-strategies-pdf-8957634445

*Observational study design filter adapted from:* 

Scottish Intercollegiate Guidelines Network (SIGN). Search filters: observational studies. Medline. Edinburgh: SIGN, Last Modified 24/04/17 Available from: https://www.sign.ac.uk/what-we-do/methodology/search-filters/

NICE (18 December 2020) [accessed 17.8.21] COVID-19 rapid guideline: managing the long-term effects of

### PubMed limit:

Duffy S, de Kock S, Misso K, Noake C, Ross J, Stirk L. Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via Ovid. J Med Libr Assoc. 2016 Oct;104(4):309-312. doi: 10.3163/1536-5050.104.4.011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079494/

## Europe PMC, including medRxiv and bioRxiv preprints (Internet): up to 2024/01/04 Searched 4.1.24

https://europepmc.org/

	Results
(TITLE:"COVID-19" OR TITLE:"coronavirus" OR TITLE:"COVID" OR TITLE:"NCOV" OR TITLE:"SARS-CoV-2") AND (TITLE:"2022" OR TITLE:"2023" OR TITLE:"strain" OR TITLE:"strains" OR TITLE:"variants" OR TITLE:"mutation" OR TITLE:"mutations" OR TITLE:"omicron" OR TITLE:"omicron") AND (TITLE:"pfizer" OR TITLE:"biontech" OR TITLE:" tozinameran" OR TITLE:" Comirnaty" OR TITLE: "Pfizer-BioNTech" OR TITLE: "BNT-162b2" OR TITLE: "BNT162b2" OR TITLE: "BNT162C2" OR TITLE: "BNT-162C2" OR TITLE: "BNT-162C2" OR TITLE: "TAK-919" OR TITLE: "ITLE: "TAK-919" OR TITLE:	10

827 828 829

830

831

832

833

The Europe PMC strategy was updated on 1.2.24 (1 record) and 1.3.24 (0 records).

## Latin American and Caribbean Health Sciences Literature (LILACS) (Internet): 2022-2024/01/04 Searched 4.1.24

https://search.bvsalud.org/portal/?lang=en

Searched Title/Abstract/Subject Limited to Observational studies Limited to 2022-2024/01/04 Limited to LILACS only

845

839

((COVID OR NCOV OR coronavirus OR COVID19 OR "SARs-COV-2" OR Omicron OR omicron)) AND ((mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care unit" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUS OR HDU OR HDUS OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalisations OR Hospitalisations OR

"hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stay" OR "inpatient stays" OR "inpatient stays" OR risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazards OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR associating OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR aiRR OR aOR OR "adjusted OR" OR "disease severity" OR "severity score" OR "severity index" OR "severity of illness" OR "critical illness" OR "emergency status" OR "urgency status" OR "severe complication" OR "severe complications") ) AND ((pfizer OR biontech OR tozinameran OR Comirnaty OR "Pfizer-BioNTech" OR "pf07302048" OR "pf-07302048" OR "BNT-162b2" OR "BNT162b2" OR Pidacmeran OR "BNT162C2" OR "BNT-162C2" OR Abdavomeran OR "BNT-162B1" OR "BNT162B1" OR "BNT162A1" OR "BNT-162A1" OR "Pfizer-BioNTech" OR "2417899-77-3" OR Elasomeran OR moderna OR Spikevax OR davesomeran OR imelasomeran OR andusomeran OR "mRNA 1273" OR "mRNA1273" OR "mRNA-1273.211" OR "mRNA 1273.211" OR Spikevax OR "M-1273" OR "M1273" OR "CX-024414" OR "CX024414" OR "TAK-919" OR "TAK919" OR "2430046-03-8" OR "2457298-05-2" OR "RNA vaccine" OR "RNA vaccines" OR "RNA vaccination" OR "RNA shot" OR "RNA shots" OR "mRNA vaccine" OR "mRNA vaccines" OR "mRNA vaccination" OR "mRNA shot" OR "mRNA shots") ) AND ((2022 OR 2023 OR 2024 OR strain OR strains OR variant OR variants OR mutations OR mutation OR omikron OR Omicron OR "B.1.1.529" OR "B11529" OR xbb))

N=3

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868 869

870 871

872 873

874

875

876 877

878

879 880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

The LILACS strategy was updated on 1.2.24 (0 records) and 1.3.24 (0 records).

Cochrane COVID-19 Study Register (www): 2022-2024/01/04 Searched 4.1.24

https://covid-19.cochrane.org/

Limited to Observational cohort studies. Limited 2022-2024/01/04

(mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care unit" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUS OR HDU OR HDUS OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalisations OR "hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stay" OR "inpatient stays" OR "inpatient stays" OR risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazardous OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR associating OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR aiRR OR aOR OR "adjusted OR" OR "disease severity" OR "severity score" OR "severity index" OR "severity of illness" OR "critical illness" OR "emergency status" OR "urgency status" OR "severe complication" OR "severe complications") AND (pfizer OR biontech OR tozinameran OR Comirnaty OR "Pfizer-BioNTech" OR "pf07302048" OR "pf-07302048" OR "BNT-162b2" OR "BNT162b2" OR Pidacmeran OR "BNT162C2" OR "BNT-162C2" OR Abdavomeran OR "BNT-162B1" OR "BNT162B1" OR "BNT162A1" OR "BNT-162A1" OR "Pfizer-BioNTech" OR "2417899-77-3" OR Elasomeran OR moderna OR Spikevax OR davesomeran OR imelasomeran OR andusomeran OR "mRNA 1273" OR "mRNA1273" OR "mRNA-1273.211" OR "mRNA 1273.211" OR Spikevax OR "M-1273" OR "M1273" OR "CX-024414" OR "CX024414" OR "TAK-919" OR "TAK919" OR "2430046-03-8" OR "2457298-05-2" OR "RNA vaccine" OR "RNA vaccines" OR "RNA vaccination" OR "RNA shot" OR "RNA

shots" OR "mRNA vaccine" OR "mRNA vaccines" OR "mRNA vaccination" OR "mRNA shot" OR "mRNA shots") AND (2022 OR 2023 OR 2024 OR strain OR strains OR variant OR variants OR mutations OR mutation OR omikron OR Omicron OR "B.1.1.529" OR "B11529" OR xbb) AND (cohort OR cohorts OR observational OR "follow up" OR followup OR epidemiologic OR epidemiological OR longterm OR "long term" OR longitudinal OR prospective)

## N=(1551 studies) 1792 references

904

905

906

907

908

909 910

911 912

913 914

915

916

917 918

919

920 921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947 948

949 950

951

952

953

954

955

The Cochrane COVID-19 Study Register strategy was updated on 1.2.24 (1 record) and 1.3.24 (0 records).

# WHO COVID-19 (Internet): 2022-2024/01/03 Searched 3.1.24

https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/?lang=en

Limited to Observational and cohort studies. Limited 2022-2023.

(ti:(mortality OR death OR deaths OR fatal OR fatality OR fatalities OR survival OR "close attention unit" OR "close attention units" OR "intensive care" OR "respiratory care unit" OR "respiratory care units" OR "special care unit" OR "special care units" OR "high dependency unit" OR "high dependency units" OR ICU OR ICUs OR CCU OR CCus OR GICU OR GICUS OR HDU OR HDUS OR ITU OR ITUS OR Hospitalized OR Hospitalised population OR Hospitalization OR Hospitalisation OR Hospitalisations OR "hospital Admission" OR "hospital Admissions" OR "Critical Care" OR "length of stay" OR "duration of stay" OR "extended stay" OR "prolonged stay" OR "hospital stay" OR "in-patient stay" OR "inpatient stay" OR "inpatient stays" OR "inpatient stays" OR risk OR risks OR risky OR danger OR dangers OR dangerous OR association OR associations OR peril OR jeopardy OR jeopardise OR jeopardize OR threat OR threats OR chance OR chances OR hazard OR hazards OR hazardous OR gamble OR gambles OR gambling OR probability OR probabilities OR "at stake" OR endanger OR endangers OR endangered OR endangering OR associate OR associates OR associating OR association OR likelihood OR likelihoods OR possibility OR possibilities OR correlation OR correlations OR odds OR morbidity OR comorbidity OR "co-morbidity" OR morbidities OR comorbidities OR "co-morbidities" OR incidence OR prevalence OR predict OR predicted OR predictive OR prognosis OR prediction OR predictions OR HR OR RR OR aiRR OR aOR OR "adjusted OR" OR "disease severity" OR "severity score" OR "severity index" OR "severity of illness" OR "critical illness" OR "emergency status" OR "urgency status" OR "severe complication" OR "severe complications")) AND (pfizer\$ OR biontech OR tozinameran OR Comirnaty OR "Pfizer-BioNTech" OR "pf07302048" OR "pf-07302048" OR "BNT-162b2" OR "BNT162b2" OR Pidacmeran OR "BNT162C2" OR "BNT-162C2" OR Abdavomeran OR "BNT-162B1" OR "BNT162B1" OR "BNT162A1" OR "BNT-162A1" OR "Pfizer-BioNTech" OR "2417899-77-3" OR Elasomeran OR moderna OR Spikevax OR davesomeran OR imelasomeran OR andusomeran OR "mRNA 1273" OR "mRNA1273" OR "mRNA-1273.211" OR "mRNA 1273.211" OR Spikevax OR "M-1273" OR "M1273" OR "CX-024414" OR "CX024414" OR "TAK-919" OR "TAK919" OR "2430046-03-8" OR "2457298-05-2" OR "RNA vaccine" OR "RNA vaccines" OR "RNA vaccination" OR "RNA shot" OR "RNA shots" OR "mRNA vaccine" OR "mRNA vaccines" OR "mRNA vaccination" OR "mRNA shot" OR "mRNA shots")

## N=477

\* WHO COVID-19 database ceased on June 2023, therefore update searches were not necessary.

## 1.2. Study Selection

Identified studies were first assessed at title and abstract level using the Rayyan tool<sup>1</sup> by 2 independent reviewers to determine whether they met the inclusion criteria. Disagreements were resolved by discussion until a consensus was reached. Full text screening was performed on all studies that met the inclusion criteria at title and abstract level.

### 1.3. Data Extraction

- 957 One reviewer extracted data on study and patient characteristics, and outcomes of interest into a predefined 958 table. A second reviewer verified the accuracy of extraction. For studies that also coincided with other SARS-
- 959 CoV-2 variants, only data relating to the Omicron variant were extracted, as defined by the study.

#### 960 1.4. Quality Assessment

- 961 Studies were assessed as having high, moderate, or low risk of bias using the Newcastle-Ottawa scale for cohort
- 962 and case-control studies<sup>2</sup> and the Joanna Briggs Institute checklist for cross-sectional studies.<sup>3</sup> A single reviewer
- 963 conducted the assessments, and a second reviewer verified the results. Discrepancies were resolved by
- 964 discussion.

956

966

#### 965 1.5. Data Analysis

### 1.5.1 Statistical Analysis

- 967 Odds ratios (ORs), hazard ratios (HRs), and rate ratios are considered equal estimates and were therefore
- 968 combined. Weights were calculated using the inverse variance method (weight= 1/variance). Random-effects
- 969 DerSimonian and Laird models<sup>5</sup> were fitted to calculate pooled relative risk (RR) and 95% confidence interval
- 970 for all outcomes. Population analyses that included fewer than 5 subgroups were not conducted due to the
- 971 challenges associated with combining few studies. 'Subgroup' refers to the types of
- 972 immunocompromising/immunosuppressive conditions of interest. It often contains any additional information
- 973 that differentiates the condition from another one included in the same meta-analysis by the same study (e.g.
- 974 'men who take immunosuppressants' and 'women who take immunosuppressants'). 'Subgroup' is often used
- 975 interchangeably with 'study'. However, considering that some studies included multiple subgroups that are
- 976 included in the same meta-analysis, for clarity they are referred to in this report as 'subgroups'.
- 977 Heterogeneity was measured using Cochran's Q statistic, with statistical significance set as P < .05, and
- 978 quantified by the I<sup>2</sup> test. The I<sup>2</sup> statistic as defined by the Cochrane Handbook for Systematic Reviews of
- 979 Interventions<sup>6</sup> was used for thresholds for interpretation: 0% to 40% might not be important; 40% to 60% may
- 980 represent moderate heterogeneity; 60% to 90% may represent substantial heterogeneity; 90% to 100% may
- 981 represent considerable heterogeneity. Publication bias was assessed using funnel plots and the Egger's test.<sup>7</sup>

#### 982 1.5.2 Additional Subgroup Analysis

983 Studies that exclusively included children were excluded from all analyses. For analyses for which those studies 984 were eligible, an additional sensitivity analysis called 'Including children' was conducted. Additional subgroup 985 analyses included the '> 50 years' population included only participants older than 50 years, the 'COVID-19-986 related outcomes only' population included only outcomes that were explicitly caused by COVID-19. Patients

987 with renal disease were further analyzed for the 'Death' outcome in 2 population subgroups: 'chronic kidney

988 disease (CKD) stage 3' (included CKD stage 3 subgroups) and 'advanced renal disease' (included CKD stage 5, 989

renal failure, end-stage kidney disease, and renal replacement therapy subgroups).

### 990 2. Supplemental eResults 991 2.1. Studies With Insufficient Numbers for Meta-Analysis 992 Due to insufficient number of subgroups, meta-analyses were not conducted for the following outcomes and 993 immunocompromising/immunosuppressing (IC/IS) conditions: intensive care unit (ICU) admission for people 994 with autoimmune diseases (n = 2) and transplant (n = 2); death (n = 1), hospitalization (n = 3), ICU (n = 0), or 995 combined outcomes (n = 2) for people with HIV; and hospitalization for people with liver disease (n = 2) (Table 996 3). Studies and subgroups identified for each of these conditions are narratively described in Section 2.6 of the 997 Supplement. 998 2.2. Risk of Death – Other Subgroup Analyses 999 Subgroup analyses differed from the main analysis and showed that people with either autoimmune or liver 1000 diseases did not have a significantly higher risk of death when they were hospitalized before the start of the 1001 study (Supplemental eTable 5). 1002 2.3. Risk of ICU - Sensitivity and Subgroup Analyses 1003 Statistical significance was lost in the group of people with cancer in the least adjusted analysis (P = .0647) 1004 (Supplemental eTable 8). The 'Leave-1-out' sensitivity analyses assessed the effect of removing individual 1005 studies on pooled estimates. Removing the Starkey 2023 study<sup>8</sup> from the cancer group analysis and the Russell 1006 20239 or Mayer 202310 studies from the renal disease group resulted in a loss of significance for each analysis; 1007 these studies were not outliers but had more weight than other studies. 1008 Subgroup analyses showed that people with cancer who were hospitalized before the study did not have a 1009 significant risk of ICU admission (Supplemental eTable 9). Additionally, people with renal disease did not 1010 have a significant risk of ICU admission in any of the analyzed subgroups, which is likely due to the low 1011 number of studies included for each subgroup. 1012 1013 2.4. Risk of Any Combination of Outcomes (Death, Hospitalization, or ICU Admission) 1014 For all assessed IC/IS conditions (autoimmune diseases, cancer, IC/IS, liver disease, renal diseases, or 1015 transplant), patients with the condition had a significantly increased risk of the 'Combined' outcome (P < .05; 1016 Figure 2D) in comparison with patients without the condition. Statistical heterogeneity was substantial for 1017 studies of patients with autoimmune diseases, and considerable for all other groups (Figure 2D). Publication 1018 bias was detected in studies of patients with cancer or liver disease, and could not be assessed for studies of 1019 patients with autoimmune diseases or transplant recipients (Supplemental eTable 10). 1020 All sensitivity analyses results had the same degree of significance as the main analysis for the risk of 1021 hospitalization outcome (Supplemental eTable 10), indicating the robustness of the main analysis results. 1022 Subgroup analyses demonstrated that patients with autoimmune diseases or cancer did not have a significant risk 1023 of combined outcomes if they were hospitalized prior to the study (Supplemental eTable 11). Additionally, 1024 patients with liver disease did not have a higher risk of combined outcomes for COVID-19-related only 1025 outcomes or if they were not hospitalized before the study.

## 1026 2.5. Supplemental eTables

1027

1028

## 2.5.1. Supplemental eTable 1. Inclusion and Exclusion Criteria for Studies

## Included in This Analysis

Characteristic	Inclusion criteria	Exclusion criteria
Population	<ul> <li>Immunocompromised/immunosuppressed:</li> <li>Immunocompromised/immunosuppressed groups</li> <li>Solid organ transplant (current or historic)</li> <li>Stem cells transplant (current or historic)</li> <li>Bone marrow transplant (current or historic)</li> <li>Any malignancy (current or historic)</li> <li>Autoimmune conditions</li> <li>Any liver diseases</li> <li>Chronic kidney disease</li> <li>Advanced or untreated HIV</li> <li>End-stage kidney disease</li> </ul>	<ul> <li>All patients with conditions of interest to prevent synergizing effects</li> <li>High risk patient groups, i.e. patients who are eligible to take antivirals to prevent severe COVID-19</li> <li>Highly vulnerable populations, such as the elderly in nursing homes</li> </ul>
Comparators	<ul> <li>Non-immunocompromised/non-immunosuppressed people</li> <li>General population</li> </ul>	Non-comparative studies
Outcomes	<ul> <li>Risk of:         <ul> <li>Hospitalization</li> <li>ICU admission</li> </ul> </li> <li>Death</li> <li>Combined: other potential COVID-19 severity outcomes, where severity is measured by any of the outcomes outlined above</li> <li>Outcomes that were not explicit 'Hospitalization' or 'ICU', such as mechanical ventilation, were also included in this review as part of 'ICU' or 'Hospitalization' outcomes, depending on the definitions</li> </ul>	Studies that do not report at least 1 relevant outcome of interest
Outcome measures	<ul> <li>Risk ratio</li> <li>Rate ratio</li> <li>Hazard ratio</li> <li>Odds ratio</li> <li>Incidence rate ratios</li> </ul>	-

Study design	Observational (cohort, case-control, cross- sectional)	Interventional studies, such as randomized/non- randomized controlled trials
Language	Studies with full text published in English will be included. All potentially relevant publications without English language full text will be listed	Studies without a full text published in English
Timeframe	<ul> <li>Majority of cases contracted the Omicron variant, as defined by study authors. When the study period was not described as predominantly Omicron, the cut-off date of December 2021, when the WHO declared Omicron as a new variant of concern,<sup>11</sup> was chosen</li> </ul>	Studies not reporting data on the Omicron variant
Publication date	Studies published after 1 Jan 2022	Studies published prior to 1 Jan 2022
Publication type	Full-text articles	<ul><li>Conference abstracts</li><li>Letters</li><li>Case reports</li><li>Editorials</li></ul>
Countries	- Any	-

1029

1030

ICU, intensive care unit; WHO, World Health Organization.

## **2.5.2 Supplemental eTable 2. Omicron Period in the Included Studies**

Year	20	21						202	22											20	23					
Study/month	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
Agrawal 2022																										
AlBahrani 2022																										
Arbel 2023																										
Arbel 2022																										
Bahremand 2023																										
Bao 2022																										
Bedston 2024																										
Benites-Godínez 2023																										
Beppu 2024																										
Beraud 2023																										
Bournia 2023																										
Briciu 2023 Brosh-Nissimov 2023																										
Chen 2023																										
Chen 2024																										
Choi 2023																										
de Prost 2022																										
de Prost 2023																										
Drummond 2023																										
Elamin 2024																										
Ellis 2023																										

Year	20	21						202	22											20	23					
Study/month	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
Evans 2023																										
Favia 2023																										
Flacco 2023																										
Gazit 2022																										
Griggs 2024																										
Guo 2023																										
Helmy 2023 <sup>a</sup>																										
Hippisley-Cox 2023 Jamaati 2023																										
Kang 2023																										
Karageorgou 2023																										
Kim 2023																										
Klein 2023																										
Konermann 2023																										
Lee 2024																										
Li 2024																										
Li 2023																										
Liu 2023																										
Lu 2022																										
Mayer 2023																										
Mendoza-Cano 2023																										
Mizrahi Reuveni 2023																										
Morris 2023																										
Nab 2023																										

Year	20	21						202	22											20	23					
Study/month	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
Nevejan 2022																										
O'Leary 2023																										
Overvad 2022																										
Parajuli 2023																										
Parra-Bracamonte 2023																										
Patton 2023																										
Puyat 2023																										
Radhakrishnan 2023																										
Rasmussen 2023																										
Risk 2022																										
Russell 2023																										
Shakor 2023																										
Shi 2023																										
Simmons 2023																										
Skarbinski 2022																										
Starkey 2023																										
Svensson 2023																										
Tsujimoto 2023																										
Vo 2022																										
Wang 2023																										
Ward 2024																										
Xin 2024																										
Xing 2023																										
Yang 2023																										

Risk of severe COVID-19 outcomes: Immunocompromised SLR and MA (Supplemental Materials)

Year	20	21						20	22											20	23					
Study/month Zhang 2022	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
Zhao 2023																										
Zhu 2023																										

<u>2</u> 3 4 <sup>a</sup>Helmy 2023 did not explicitly mention the Omicron variant and study period; however, it was included based on the following sentence: "This prospective observational study was conducted in a university hospital after the institutional research ethics board approval (N-24-2022)". Green indicates the Omicron study period of the studies included in the analyses; Orange indicates the Omicron study period of the studies excluded from the analyses.

## 2.5.3. Supplemental eTable 3. Risk of Bias of the Included Studies Using NOS

## and JBI Tools

1035

1036

Study	Low	Medium	High
Agrawal 2022 <sup>12</sup>			
AlBahrani 2022 <sup>13</sup>			
Arbel 2022 <sup>14</sup>			
Arbel 2023 <sup>15</sup>			
Bahremand 2023 <sup>16</sup>			
Bao 2022 <sup>17a</sup>			
Bedston 2024 <sup>18</sup>			
Benites-Godínez 2023 <sup>19</sup>			
Beppu 2024 <sup>20</sup>			
Beraud 2023 <sup>21</sup>			
Bournia 2023 <sup>22</sup>			
Briciu 2023 <sup>23</sup>			
Brosh-Nissimov 2023 <sup>24</sup>			
Chen 2023 <sup>25a</sup>			
Chen 2024 <sup>26</sup>			
Choi 2023 <sup>27</sup>			
de Prost 2022 <sup>28</sup>			
de Prost 2023 <sup>29</sup>			
Drummond 2023 <sup>30</sup>			
Elamin 2024 <sup>31</sup>			
Ellis 2023 <sup>32</sup>			
Evans 2023 <sup>33</sup>			
Favia 2023 <sup>34</sup>			
Flacco 2023 <sup>35</sup>			
Gazit 2022 <sup>36</sup>			
Griggs 2024 <sup>37</sup>			
Guo 2023 <sup>38</sup>			
Helmy 2023 <sup>39</sup>			
Hippisley-Cox 2023 <sup>40</sup>			
Jamaati 2023 <sup>41</sup>			
Kang 2023 <sup>42</sup>			
Karageorgou 202343			
Kim 2023 <sup>44</sup>			

Study	Low	Medium	High
Klein 2023 <sup>45</sup>			J
Konermann 2023 <sup>46</sup>			
Lee 2024 <sup>47</sup>			
Li 2023 <sup>48a</sup>			
Li 2024 <sup>49</sup>			
Liu 2023 <sup>50</sup>			
Lu 2022 <sup>51a</sup>			
Mayer 2023 <sup>10</sup>			
Mendoza-Cano 2023 <sup>52</sup>			
Mizrahi Reuveni 2023 <sup>53</sup>			
Morris 2023 <sup>54b</sup>			
Nab 2023 <sup>55</sup>			
Nevejan 2022 <sup>56</sup>			
O'Leary 2023 <sup>57</sup>			
Overvad 2022 <sup>58</sup>			
Parajuli 2023 <sup>59</sup>			
Parra-Bracamonte 2023 <sup>60</sup>			
Patton 2023 <sup>61</sup>			
Puyat 2023 <sup>62</sup>			
Radhakrishnan 2023 <sup>63</sup>			
Rasmussen 2023 <sup>64</sup>			
Risk 2022 <sup>65</sup>			
Russell 2023 <sup>9</sup>			
Shakor 2023 <sup>66a,b</sup>			
Shi 2023 <sup>67</sup>			
Simmons 2023 <sup>68</sup>			
Skarbinski 2022 <sup>69</sup>			
Starkey 2023 <sup>8</sup>			
Svensson 2023 <sup>70</sup>			
Tsujimoto 2023 <sup>71</sup>			
Vo 2022 <sup>72</sup>			
Wang 2023 <sup>73</sup>			
Ward 2024 <sup>74</sup>			
Xin 2024 <sup>75</sup>			
Xing 2023 <sup>76b</sup>			
Yang 2023 <sup>77</sup>			

Risk of severe COVID-19 outcomes: Immunocompromised SLR and MA (Supplemental Materials)

Study	Low	Medium	High
Zhang 2022 <sup>78</sup>			
Zhao 2023 <sup>79</sup>			
Zhu 2023 <sup>80</sup>			

1037

Abbreviations: JBI, Joanna Briggs Institute; NOS, Newcastle-Ottawa scale.

1038 1039

<sup>a</sup>Risk of bias was assessed using the JBI critical appraisal checklist for analytical cross-sectional studies. Green indicates low risk of bias, amber – medium, and red – high.

104( 104) 104; 104;

<sup>b</sup>Shakor 2023 was assessed using the JBI critical appraisal checklist for analytical cross-sectional studies. For 2 of the questions the study was unclear (3. Was the exposure measured in a valid and reliable way?; 4. Were objective, standard criteria used for measurement of the condition?). For 1 question the answer was no (5. Were confounding factors identified?). For 1 question, the answer was not applicable (6. Were strategies to deal with confounding factors stated [adjustment during analysis]?)

#### 2.5.4. Supplemental eTable 4. Main and Sensitivity Analyses Results of the 'Death' Outcome 1045

	Main analysis (RR (95% CI), <i>P</i> value, I <sup>2</sup> )	Statistical evidence of publication bias (yes/no)	Least adjusted (RR [95% C]), <i>P</i> value, I <sup>2</sup> )	Only adjusted (RR [95% C]), <i>P</i> value, l <sup>2</sup> )	Excluding studies for population overlap (RR [95% CI], P value, I <sup>2</sup> )	Leave-1-out (yes/no for significant difference of removing a subgroup)
Autoimmune diseases	1.33 (1.20, 1.48), P < .05, I <sup>2</sup> = 65%	No	1.39 (1.29, 1.49), <i>P</i> < .001, I <sup>2</sup> = 31.92%	1.34 (1.20, 1.48), <i>P</i> < .001, I <sup>2</sup> = 68.15%	1.33 (1.21, 1.48), P < .001, I <sup>2</sup> = 64.61%	No
Cancer	2.40 (1.22, 2.74), P < .05, I <sup>2</sup> = 97%	No	2.49 (1.90, 3.26), <i>P</i> < .001, 1 <sup>2</sup> = 98.94%	2.53 (2.21, 2.90), <i>P</i> < .001, 1 <sup>2</sup> = 96.94%	2.40 (2.11, 2.74), P < .001, I <sup>2</sup> = 96.81%	No
Immunocompromised/ immunosuppressed	2.17 (1.77, 2.66), P < .05, I <sup>2</sup> = 97%	No	2.25 (1.83, 2.75), <i>P</i> < .001, 1 <sup>2</sup> = 97.02%	2.20 (1.77, 2.72), <i>P</i> < .001, 1 <sup>2</sup> = 97.16%	2.18 (1.77, 2.67), P < .001, I <sup>2</sup> = 96.9%	No
Liver disease	1.79 (1.31, 2.43), P < .05, I <sup>2</sup> = 96%	No	1.99 (1.52, 2.59), <i>P</i> < .001, 1 <sup>2</sup> = 94.63%	1.85 (1.35, 2.53), <i>P</i> < .001, 1 <sup>2</sup> = 96.47%	1.79 (1.31, 2.43), P < .001, I <sup>2</sup> = 95.83%	No
Renal disease	2.15 (1.88, 2.46), P < .05, I <sup>2</sup> = 98%	Yes	2.21 (1.93, 2.53), <i>P</i> < .001, 1 <sup>2</sup> = 98.28%	2.24 (1.94, 2.58), <i>P</i> < .001, 1 <sup>2</sup> = 98.41%	2.26 (1.96, 2.60), P < .001, I <sup>2</sup> = 98.29%	No
Transplant	6.78 (4.41, 10.43), P < .05, I <sup>2</sup> = 80%	Yes	6.78 (4.41, 10.43), <i>P</i> < .001, I <sup>2</sup> = 79.86%	8.50 (5.70, 12.67), <i>P</i> < .001, I <sup>2</sup> = 74.81%	6.78 (4.41, 10.43), P < .001, I <sup>2</sup> = 79.86%	No

Abbreviations: CI, confidence interval; RR, risk ratio.
All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis.

## 2.5.5. Supplemental eTable 5. Main and Population Subgroup Analyses Results of the 'Death' Outcome for All Population

## Subgroups of Interest

1048

1049

	Main analysis (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	General population (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Hospitalized population (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	COVID-19 related only (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Subgroup of a population older than 50 years (RR [95% CI], P value, I <sup>2</sup> )	CKD stage 3 (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Advanced renal disease (RR [95% CI], P value, I <sup>2</sup> )
Autoimmune diseases	1.33 (1.20, 1.48), <i>P</i> < .05, l <sup>2</sup> = 65%	1.33 (1.20, 1.48), <i>P</i> < .001, I <sup>2</sup> = 70.93%	1.84 (0.72, 4.69), <i>P</i> = .202, I <sup>2</sup> = 0%	1.38 (1.27, 1.51), <i>P</i> < .001, I <sup>2</sup> = 50.04%	1.46 (1.24, 1.71), <i>P</i> < .001, $I^2 = 0\%$	NA	NA
Cancer	2.40 (1.22, 2.74), <i>P</i> < .05, l <sup>2</sup> = 97%	2.61 (2.16, 3.16), <i>P</i> < .001, I <sup>2</sup> = 97.48%	2.07 (1.55, 2.77), <i>P</i> < .001, I <sup>2</sup> = 91.12%	2.78 (2.20, 3.51), <i>P</i> < .001, I <sup>2</sup> = 97.6%	2.81 (2.39, 3.31), <i>P</i> < .001, $I^2 = 21.09\%$	NA	NA
Immunocompromised/ immunosuppressed	2.17 (1.77, 2.66), <i>P</i> < .05, l <sup>2</sup> = 97%	2.303 (1.77, 3.00), <i>P</i> < .001, I <sup>2</sup> = 96.89%	1.82 (1.38, 2.41), <i>P</i> < .001, I <sup>2</sup> = 60.62%	2.61 (2.09, 3.25), <i>P</i> < .001, I <sup>2</sup> = 93.66%	NA	NA	NA
Liver disease	1.79 (1.31, 2.43), <i>P</i> < .05, I <sup>2</sup> = 96%	2.767 (2.19, 3.50), <i>P</i> < .001, I <sup>2</sup> = 70.63%	1.20 (0.94, 1.53), <i>P</i> = .142, I <sup>2</sup> = 85.03%	3.34 (2.95, 3.78), <i>P</i> < .001, I <sup>2</sup> = 0%	2.677 (2.00, 3.59), <i>P</i> < .001, $I^2 = 0\%$	NA	NA
Renal disease	2.15 (1.88, 2.46), <i>P</i> < .05, I <sup>2</sup> = 98%	2.558 (2.09, 3.14), <i>P</i> < .001, $I^2 = 98.02\%$	1.35 (1.18, 1.55), <i>P</i> < .001, I <sup>2</sup> = 93.47%	2.51 (2.00, 3.16), <i>P</i> < .001, $I^2 = 98.95\%$	1.88 (1.23, 2.87), <i>P</i> = .00367, l <sup>2</sup> = 68.48%	1.38 (1.17, 1.64), <i>P</i> < .001, $I^2 = 94\%$	3.57 (2.06, 6.19), <i>P</i> < .001, I <sup>2</sup> = 98%
Transplant	6.78 (4.41, 10.43), <i>P</i> < .05, l <sup>2</sup> = 80%	8.499 (5.70, 12.67), <i>P</i> < .001, I <sup>2</sup> = 74.81%	2.30 (1.08, 4.88), <i>P</i> = .03, I <sup>2</sup> = 0%	8.50 (5.70, 12.67), <i>P</i> < .001, I <sup>2</sup> = 74.81%	NA	NA	NA

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; NA, not applicable; RR, risk ratio.

All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis; Orange indicates that the significance of the result is different from the main analysis.

### 2.5.6. Supplemental eTable 6. Main and Sensitivity Analyses Results of the 'Hospitalization' Outcome 1053

	Main analysis (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Statistical evidence of publication bias (yes/no)	Least adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Only adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Excluding studies for population overlap (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Leave-1-out (yes/no for significant difference of removing a subgroup)
Autoimmune diseases	1.76 (1.42, 2.16), <i>P</i> < .05, l <sup>2</sup> = 97%	NA	1.79 (1.44, 2.22), <i>P</i> < .001, I <sup>2</sup> = 97.54%	1.76 (1.42, 2.17), <i>P</i> < .001, I <sup>2</sup> = 97.36%	1.76 (1.42, 2.17), P < .001, I <sup>2</sup> = 97.36%	No
Cancer	2.18 (1.82, 2.61), <i>P</i> < .05, l <sup>2</sup> = 98%	No	2.30 (1.74, 3.03), <i>P</i> < .001, I <sup>2</sup> = 99.25%	2.18 (1.82, 2.61), <i>P</i> < .001, I <sup>2</sup> = 98.02%	2.18 (1.82, 2.61), P < .001, I <sup>2</sup> = 98.02%	No
Immunocompromised/ immunosuppressed	2.75 (2.11, 3.59), <i>P</i> < .05, l <sup>2</sup> = 98%	No	2.77 (2.14, 3.59), <i>P</i> < .001, I <sup>2</sup> = 97.93%	2.75 (2.11, 3.59), <i>P</i> < .001, I <sup>2</sup> = 98.05%	2.75 (2.11, 3.59), P < .001, I <sup>2</sup> = 98.05%	No
Renal disease	2.13 (1.64, 2.76), <i>P</i> < .05, l <sup>2</sup> = 99%	No	2.14 (1.65, 2.76), <i>P</i> < .001, I <sup>2</sup> = 98.7%	2.13 (1.64, 2.76), <i>P</i> < .001, I <sup>2</sup> = 98.72%	2.13 (1.64, 2.76), P < .001, I <sup>2</sup> = 98.72%	No
Transplant	6.75 (3.41, 13.37), <i>P</i> < .05, I <sup>2</sup> = 98%	NA	6.75 (3.4, 13.37), <i>P</i> < .001, I <sup>2</sup> = 97.96%	5.34 (2.98, 9.56), <i>P</i> < .001, $I^2 = 93.81\%$	6.75 (3.41, 13.37), P < .001, I <sup>2</sup> = 97.96%	No

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.
All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis.

## 2.5.7. Supplemental eTable 7. Main and Population Subgroup Analyses Results of the 'Hospitalization' Outcome for All

## Subgroups of Interest

1056

1057

	Main analysis (RR [95% Cl], <i>P</i> value, l <sup>2</sup> )	COVID-19 related only (RR [95% CI], <i>P</i> value, I²)	Subgroup of a population older than 50 years (RR [95% Cl], <i>P</i> value, l <sup>2</sup> )	Including children (RR [95% Cl], <i>P</i> value, l²)
Autoimmune diseases	1.76 (1.42, 2.16), <i>P</i> < .05, I <sup>2</sup> = 97%	1.81 (1.48, 2.20), <i>P</i> < .001, I <sup>2</sup> = 94.3%	NA	NA
Cancer	2.18 (1.82, 2.61), <i>P</i> < .05, I <sup>2</sup> = 98%	2.52 (1.93, 3.30), <i>P</i> < .001, I <sup>2</sup> = 98.39%	NA	NA
Immunocompromised/ immunosuppressed	2.76 (2.11, 3.59), <i>P</i> < .05, I <sup>2</sup> = 98%	2.88 (2.06, 4.034), <i>P</i> < .001, I <sup>2</sup> = 98.41%	NA	2.92 (2.24, 3.81), <i>P</i> < .001, I <sup>2</sup> = 97.96%
Renal disease	2.13 (1.64, 2.76), <i>P</i> < .05, I <sup>2</sup> = 99%	2.25 (1.57, 3.21), <i>P</i> < .001, I <sup>2</sup> = 98.96%	1.79 (1.14, 2.82), <i>P</i> = .0114, I <sup>2</sup> = 87.14%	NA
Transplant	6.75 (3.41, 13.37), <i>P</i> < .05, I <sup>2</sup> = 98%	6.75 (3.41, 13.37), <i>P</i> < .001, I <sup>2</sup> = 97.96%	NA	NA

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.

All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis.

# 2.5.8. Supplemental eTable 8. Main and Sensitivity Analyses Results of the 'ICU Admission' Outcome

	Main analysis (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Statistical evidence of publication bias (yes/no)	Least adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Only adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Excluding studies for population overlap (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Leave-1-out (yes/no for significant difference of removing a subgroup)
Cancer	2.09 (1.13, 3.89), P < .05, I <sup>2</sup> = 98%	NA	2.00 (0.96, 4.16), <i>P</i> = .0647, I <sup>2</sup> = 98.93%	2.66 (1.34, 5.26), <i>P</i> = .00498, I <sup>2</sup> = 98.72%	2.10 (1.13, 3.89), P = .019, I <sup>2</sup> = 98.3%	Yes
Immunocompromised/ immunosuppressed	3.38 (2.37, 4.83), <i>P</i> < .05, I <sup>2</sup> = 79%	NA	3.43 (2.41, 4.88), <i>P</i> < .001, I <sup>2</sup> = 78.32%	4.42 (3.92, 4.99), <i>P</i> < .001, I <sup>2</sup> = 0%	3.38 (2.37, 4.83), P < .001, I <sup>2</sup> = 78.72%	No
Liver disease	1.27 (1.07, 1.52), P < .05, I <sup>2</sup> = 68%	NA	1.41 (1.14, 1.75), <i>P</i> = .0017, I <sup>2</sup> = 86.79%	1.28 (1.07, 1.52), <i>P</i> = .00741, I <sup>2</sup> = 68.18%	1.28 (1.07, 1.52), P = .00741, I <sup>2</sup> = 68.18%	No
Renal disease	1.96 (1.19, 3.22), P < .05, I <sup>2</sup> =	No	2.25 (1.33, 3.79), <i>P</i> = .00236, I <sup>2</sup> = 96.8%	2.89 (1.56, 5.34), <i>P</i> < .001, I <sup>2</sup> = 97.74%	1.96 (1.19, 3.22), P = .00802, I <sup>2</sup> = 96.05%	Yes

1060

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.
All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis; Orange indicates that the significance of the result is different from the main analysis.

# 2.5.9. Supplemental eTable 9. Main and Population Subgroup Analyses Results of the 'ICU' Outcome for All Population

# Subgroups of Interest

1064

1065

	Main analysis (RR [95% Cl], <i>P</i> value, l <sup>2</sup> )	General population (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Hospitalized population (RR [95% CI], <i>P</i> value, I²)	COVID-19 related only (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Subgroup of a population older than 50 years (RR [95% CI], <i>P</i> value, I <sup>2</sup> )
Cancer	2.09 (1.13, 3.89), <i>P</i> < .05, l <sup>2</sup> = 98%	3.37 (1.10, 10.37), <i>P</i> = .0337, I <sup>2</sup> = 98.36%	1.59 (0.83, 3.06), <i>P</i> = .163, I <sup>2</sup> = 85.56%	3.85 (1.48, 10.05), <i>P</i> = .00581, I <sup>2</sup> = 97.6%	NA
Immunocompromised/ immunosuppressed	3.38 (2.37, 4.83), <i>P</i> < .05, I <sup>2</sup> = 79%	4.49 (3.97, 5.08), <i>P</i> < .001, I <sup>2</sup> = 0%	2.39 (1.05, 5.46), <i>P</i> = .0379, I <sup>2</sup> = 71.07%	4.42 (3.91, 4.98), <i>P</i> < .001, I <sup>2</sup> = 0%	NA
Liver disease	1.27 (1.07, 1.52), <i>P</i> < .05, I <sup>2</sup> = 68%	NA	1.28 (1.07, 1.52), <i>P</i> = .00741, I <sup>2</sup> = 68.18%	NA	NA
Renal disease	1.96 (1.19, 3.22), <i>P</i> < .05, l <sup>2</sup> = 96%	3.00 (0.45, 20.11), <i>P</i> = .259, l <sup>2</sup> = 98.61%	1.53 (0.89, 2.62), <i>P</i> = .122, I <sup>2</sup> = 81.33%	3.20 (0.92, 11.07), <i>P</i> = .067, I <sup>2</sup> = 91.86%	NA

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.

All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis; Orange indicates that the significance of the result is different from

# 1069 2.5.10. Supplemental eTable 10. Main and Sensitivity Analyses Results of the 'Combined' Outcome

	Main analysis (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Statistical evidence of publication bias (yes/no)	Least adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Only adjusted (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Excluding studies for population overlap (RR [95% CI], <i>P</i> value, l <sup>2</sup> )	Leave-1-out (yes/no for significant difference of removing a subgroup)
Autoimmune diseases	2.21 (1.61, 3.04), <i>P</i> < .05, I <sup>2</sup> = 89%	NA	2.21 (1.61, 3.04), <i>P</i> < .001, I <sup>2</sup> = 88.61%	2.22 (1.60, 3.08), <i>P</i> < .001, I <sup>2</sup> = 93.95%	2.21 (1.61, 3.04), P < .001, I <sup>2</sup> = 88.61%	No
Cancer	1.78 (1.45, 2.19), <i>P</i> < .05, I <sup>2</sup> = 96%	Yes	1.72 (1.40, 2.11), <i>P</i> < .001, I <sup>2</sup> = 95.85%	1.89 (1.52, 2.34), <i>P</i> < .001, I <sup>2</sup> = 96.35%	1.83 (1.48, 2.24), P < .001, I <sup>2</sup> = 96.02%	No
Immunocompromised/ immunosuppressed	2.04 (1.42, 2.94), <i>P</i> < .05, I <sup>2</sup> = 99%	No	2.05 (1.42, 2.96), <i>P</i> < .001, I <sup>2</sup> = 99.25%	1.94 (1.33, 2.83), <i>P</i> < .001, I <sup>2</sup> = 99.29%	2.05 (1.42, 2.94), P < .001, I <sup>2</sup> = 99.25%	No
Liver disease	1.50 (1.12, 2.00), <i>P</i> < .05, I <sup>2</sup> = 97%	No	1.48 (1.10, 1.97), <i>P</i> = .00864, I <sup>2</sup> = 96.64%	1.56 (1.16, 2.11), <i>P</i> = .00364, l <sup>2</sup> = 97.29%	1.50 (1.12, 2.00), P = .00678, I <sup>2</sup> = 96.65%	No
Renal disease	1.86 (1.55, 2.23), <i>P</i> < .005, I <sup>2</sup> = 95%	Yes	1.81 (1.51, 2.16), <i>P</i> < .001, I <sup>2</sup> = 94.67%	1.93 (1.58, 2.36), <i>P</i> < .001, I <sup>2</sup> = 96.13%	1.81 (1.50, 2.17), P < .001, I <sup>2</sup> = 95%	No
Transplant	8.65 (4.01, 18.65), <i>P</i> < .05, I <sup>2</sup> = 97%	NA	8.65 (4.01, 18.65), <i>P</i> < .001, I <sup>2</sup> = 97%	7.90 (3.21, 19.41), <i>P</i> < .001, I <sup>2</sup> = 97.96%	8.65 (4.01, 18.65), P < .001, I <sup>2</sup> = 97.32%	No

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.

All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis; Orange indicates that the significance of the result is different from the main analysis.

# 2.5.11. Supplemental eTable 11. Main and Population Subgroup Analyses Results of the 'Combined' Outcome for All

# 1074 Population Subgroups of Interest

1073

	Main analysis (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	General population (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Hospitalized population (RR [95% CI], <i>P</i> value, I²)	COVID-19 related only (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Subgroup of a population older than 50 years (RR [95% CI], <i>P</i> value, I <sup>2</sup> )	Including children (RR [95% CI], <i>P</i> value, I <sup>2</sup> )
Autoimmune diseases	2.21 (1.61, 3.04), P < .05, I <sup>2</sup> = 89%	2.22 (1.60, 3.08), <i>P</i> < .001, I <sup>2</sup> = 93.95%	1.91 (0.29, 12.39), P = .5, l <sup>2</sup> = 50.49%	2.21 (1.61, 3.04), <i>P</i> < .001, I <sup>2</sup> = 88.61%	NA	NA
Cancer	1.78 (1.45, 2.19), P < .05, I <sup>2</sup> = 96%	1.96 (1.58, 2.43), <i>P</i> < .001, I <sup>2</sup> = 96.71%	1.09 (0.51, 2.32), <i>P</i> = .822, I <sup>2</sup> = 75.58%	1.96 (1.59, 2.43), <i>P</i> < .001, l <sup>2</sup> = 96.4%	NA	1.75 (1.43, 2.14), <i>P</i> < .001, I <sup>2</sup> = 95.62%
Immunocompromised/ immunosuppressed	2.04 (1.42, 2.94), P < .05, I <sup>2</sup> = 99%	2.49 (1.65, 3.73), <i>P</i> < .001, I <sup>2</sup> = 98.85%	1.26 (1.18, 1.35), <i>P</i> < .001, I <sup>2</sup> = 38.73%	2.34 (1.55, 3.53), <i>P</i> < .001, I <sup>2</sup> = 98.85%	NA	NA
Liver disease	1.50 (1.12, 2.00), P < .05, I <sup>2</sup> = 97%	1.73 (0.91, 3.29), <i>P</i> = 0.0921, I <sup>2</sup> = 98.26%	1.36 (1.25, 1.48), <i>P</i> < .001, I <sup>2</sup> = 34.98%	1.59 (0.91, 2.79), <i>P</i> = .105, I <sup>2</sup> = 96.63%	NA	NA
Renal disease	1.86 (1.55, 2.23), P < .005, I <sup>2</sup> = 95%	2.39 (1.92, 2.96), <i>P</i> < .001, I <sup>2</sup> = 91.59%	1.20 (1.05, 1.37), <i>P</i> = .00688, I <sup>2</sup> = 75.43%	2.41 (1.96, 2.96), <i>P</i> < .001, I <sup>2</sup> = 89.63%	2.46 (1.46, 4.17), <i>P</i> < .001, l <sup>2</sup> = 42.3%	NA
Transplant	8.65 (4.01, 18.65), <i>P</i> < .05, I <sup>2</sup> = 97%	8.65 (4.01, 18.65), P < .001, I <sup>2</sup> = 97%	NA	8.65 (4.01, 18.65), P < .001, I <sup>2</sup> = 97%	NA	7.74 (3.75, 15.99), P < .001, I <sup>2</sup> = 96.81%

Abbreviations: CI, confidence interval; NA, not applicable; RR, risk ratio.

All estimates rounded to 2 decimal places. Green indicates that the significance of the result is the same as of the 'Main' analysis; Orange indicates that the significance of the result is different from the 'Main' analysis.

## 1078 2.6. Meta-analyses for Each IC/IS Condition: Forest Plots of Pooled RR or Narrative Descriptions for

#### **Each IC/IS Condition and Outcome**

#### 2.6.1. Autoimmune Disease

1079

1080

1081

### 2.6.1.1. Supplemental eFigure 1. Autoimmune Disease, Death Outcome (No. of Subgroups: 11)

Study (Subgroup )	RR(95%CI)						
strat = HR		-					
Hippisley-Cox 2023 [RA/SLE-Women]	1.18 [1.01; 1.37]				-		
Hippisley-Cox 2023 [IBD-Women]	1.30 [0.94; 1.80]				<del>  •</del>	_	
Hippisley-Cox 2023 [ RA/SLE-Men ]	1.24 [1.04; 1.48]				-		
Hippisley-Cox 2023 [IBD-Men]	1.10 [0.78; 1.57]			_	-		
Nab 2023 [Wave 4: RA/ lupus/ psoriasis]	1.47 [1.36; 1.59]				-		
Nab 2023 [ Wave 5: RA/ lupus/ psoriasis ]	1.50 [1.27; 1.78]				-	_	
Total	1.33 [1.20; 1.48]				<b>*</b>		
Heterogeneity: $\chi_5^2 = 10.65 (P = .06), I^2 = 53\%$							
strat = OR							
Bournia 2023 [ RA patients ]	1.73 [1.36; 2.20]					-	
Briciu 2023 [Rheumatological comorbidities]	2.29 [0.62; 6.77]				<del>                                     </del>	<del></del>	
Chen 2024 [ Autoimmune diseases ]	1.30 [0.30; 6.10]				<del>                                     </del>		
Total	1.74 [1.38; 2.19]						
Heterogeneity: $\chi_2^2 = 0.35 \ (P = .84), I^2 = 0\%$							
strat = IRR							
Svensson 2023 [Total IRD]	1.06 [0.92; 1.22]			-	-		
Ward 2024 [RA/SLE]	1.46 [1.24; 1.72]				-	-	
Total	1.24 [0.91; 1.70]			-			
Heterogeneity: $\chi_1^2 = 8.44 \ (P = .004), I^2 = 88\%$							
Total	1.33 [1.20; 1.48]				<b>\limits</b>		
			ı		1		
		0.2	0.5		1	2	


Heterogeneity:  $\chi^2_{10}$  = 28.26 (P = .002),  $I^2$  = 65% Test for subgroup differences:  $\chi^2_2$  = 4.67 (P = .10)

1082

CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; IRD, inflammatory rheumatic diseases; IRR, incidence rate ratio; OR, odds ratio; RA, rheumatoid arthritis; RR, risk ratio; SLE, systemic lupus erythematosus.

## 1085 2.6.1.2. Supplemental eFigure 2. Autoimmune Disease, Hospitalization Outcome (No. of Subgroups: 8)

Study (Subgroup )	RR(95%CI)
strat = HR	
Hippisley-Cox 2023 [ RA/SLE-women ]	1.54 [1.43; 1.66]
Hippisley-Cox 2023 [IBD-Women]	1.75 [1.54; 2.00]
Hippisley-Cox 2023 [ RA/SLE-Men ]	1.41 [1.28; 1.56]
Hippisley-Cox 2023 [IBD-Men]	2.55 [2.25; 2.88]
Russell 2022 [Multiple sclerosis]	2.84 [2.48; 3.24]
Russell 2022 [RA]	1.01 [0.93; 1.10]
Total	1.74 [1.29; 2.33]
Heterogeneity: $\chi_5^2 = 248.2 \ (P < .001), \ I^2 = 98$	%
strat = OR	
Bournia 2023 [RA]	2.02 [1.79; 2.27]
strat = IRR	
Svensson 2023 [Total IRD]	1.64 [1.54; 1.76]
Total	1.75 [1.42; 2.16]



Heterogeneity:  $\chi_7^2 = 265.28 \ (P < .001), \ I^2 = 97\%$ Test for subgroup differences:  $\chi_2^2 = 8.99 \ (P = .01)$  p-value:<0.05

1086

CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; IRD, inflammatory rheumatic diseases; IRR, incidence rate ratio; OR, odds ratio; RA, rheumatoid arthritis; RR, risk ratio; SLE, systemic lupus erythematosus.

- 1089 2.6.1.3. Autoimmune Disease, ICU Admission Outcome (No. of Studies: 2)
- The studies reported the following results for the 'ICU' outcome in the 'Autoimmune disease' populations:
- Briciu 2023<sup>23</sup> (rheumatological comorbidities): OR (95% CI): 1.60 (0.51, 4.17)
- Russell 2023<sup>9</sup> (rheumatoid arthritis): HR (95% CI): 1.15 (0.91, 1.47)
- While both studies indicated the same direction of effect increases in the risk of the 'ICU' outcome, based on the CIs, the results were not statistically significant.

## 2.6.1.4. Supplemental eFigure 3. Autoimmune Disease, Combined Outcome (No. of Subgroups: 5)

Study (Subgroup )	RR(95%CI)				
trat = HR					
Bedston 2024 [ RA/SLE ]	1.58 [1.39; 1.81]			-	
trat = OR					
Guo 2023 [ Rheumatic disease ]	0.67 [0.09; 5.25]	97	•		<u> </u>
o 2022 [ MS and transverse myelitis ]	3.36 [2.34; 4.83]			-	
otal	2.07 [0.49; 8.82]		-	<del>-</del>	_
leterogeneity: $\chi_1^2 = 2.34 \ (P = .13), I^2 = 57\%$					
trat = RR					
grawal 2022 [ RA/SLE ]	2.32 [2.20; 2.45]				
avia 2023 [Autoimmune pathologies]	4.56 [0.84; 24.76]		_	•	
otal	2.32 [2.20; 2.45]				
leterogeneity: $\chi_1^2 = 0.61 (P = .43), I^2 = 0\%$					
otal	2.21 [1.61; 3.04]			<u></u>	
		0.1	0.5	1 2	1
		0.1	0.5	1 2	
Heterogeneity: $\chi_4^2 = 35.11 \ (P < .001), I^2 = 89$	%			p-value:<0.05	
2 22 22 45				1070	


Test for subgroup differences:  $\chi_2^2$  = 28.00 (P < .001)

1096

CI, confidence interval; HR, hazard ratio; MS, multiple sclerosis; OR, odds ratio; RA, rheumatoid arthritis; RR, risk ratio; SLE, systemic lupus erythematosus.

#### 1099 2.6.2. Cancer

#### 1100 2.6.2.1. Supplemental eFigure 4. Cancer, Death Outcome (No. of Subgroups: 39)




Heterogeneity:  $\chi_{38}^2 = 1192.39 \ (P < .001), \ I^2 = 97\%$ Test for subgroup differences:  $\chi_2^2 = 4.85 \ (P = .09)$ 

1101

1102

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

## 1103 2.6.2.2. Supplemental eFigure 5. Cancer, Hospitalization Outcome (No. of Subgroups: 18)



1104

1105 CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

# 1106 2.6.2.3. Supplemental eFigure 6. Cancer, ICU Admission Outcome (No. of Subgroups: 9)

Study (Subgroup )	RR(95%CI)			
strat = HR				
Zhao 2023 [ Tumour and immunosuppression ]	2.21 [1.00; 4.88]			<u> </u>
strat = OR				
Beraud 2023 [ Solid cancer for <3 months ]	0.88 [0.21; 2.51]	_		-
Beraud 2023 [ Haematological malignancy ]	0.49 [0.12; 1.36]		-	+
Briciu 2023 [Cancer]	2.08 [1.18; 3.62]			-
Mayer 2023 [ Solid cancer ]	0.96 [0.91; 1.02]			
Starkey 2023 [ Cancer ]	2.53 [2.24; 2.86]			=
Zhang 2022 [ Malignancy ]	6.08 [2.83; 13.07]			—
Total	1.67 [0.90; 3.11]			<u></u>
Heterogeneity: $\chi_5^2 = 223.04 \ (P < .001), \ I^2 = 98\%$				
strat = RR				
Evans 2023 [ Solid tumour ≤5 years prior ]	1.22 [0.85; 1.74]			<del> </del>
Evans 2023 [Haematological malignancy ≤5 years prior]	12.37 [9.23; 16.57]			
Total	3.89 [0.40; 37.69]			+
Heterogeneity: $\chi_1^2 = 96.37 \ (P < .001), I^2 = 99\%$				
Total	2.09 [1.13; 3.89]			
				1 1
		0.1	0.5	1 2


Heterogeneity:  $\chi_8^2 = 470.08 \ (P < .001), \ I^2 = 98\%$ Test for subgroup differences:  $\chi_2^2 = 0.69 \ (P = .71)$  p-value:<0.05

1107

1108

CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

## 1109 2.6.2.4. Supplemental eFigure 7. Cancer, Combined Outcome (No. of Subgroups: 18)




1110

1111 CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

- 1112 2.6.3. HIV
- 1113 2.6.3.1. HIV, Death Outcome (No. of Studies: 1; No. of Subgroups: 1)
- 1114 The study reported the following results for the 'Death' outcome in the 'HIV' populations:
- 1115 Evans 2023<sup>33</sup> (advanced or untreated HIV): incidence rate ratio (IRR) (95% CI): 3.12 (1.13, 11.39)
- 1116 Based on the CI, Evans 2023 showed a statistically significant increase in the risk of the 'Death' outcome in the 1117 'HIV' populations.
- 1118 2.6.3.2. HIV, Hospitalization Outcome (No. of Studies: 3; No. of Subgroups: 3)
- 1119 The studies reported the following results for the 'Hospitalization' outcome in the 'HIV' populations:
- 1120 Evans 2023<sup>33</sup> (advanced or untreated HIV): IRR (95% CI): 2.26 (1.11, 4.58)
- 1121 Puyat 2023<sup>62</sup> (all people living with HIV): HR (95% CI): 1.01 (0.78, 1.29)
- 1122 Rasmussen 2023<sup>64</sup> (people with HIV at first half of year 2022): IRR (95% CI): 2.0 (1.4, 2.8)
- 1123 All studies indicated the same direction of effect – increases in the risk of the 'Hospitalization' outcome, based 1124 on the CIs, but the result of Puyat 2023 was not statistically significant.
- 1125 2.6.3.3. HIV, ICU Admission Outcome (No. of Studies: 0; No. of Subgroups: 0)
- 1126 The analysis of the 'ICU' outcome in the 'HIV' populations is not feasible as no studies were included in this 1127 analysis.
- 1128 2.6.3.4. HIV, Combined Outcome (No. of Studies: 2; No. of Subgroups: 2)
- 1129 The studies reported the following results for the 'Combined' outcome in the 'HIV' populations:
- 1130 Agrawal 2022<sup>12</sup> (HIV): RR (95% CI): 0.61 (0.35, 1.08)
- 1131 Vo 2022<sup>72</sup> (HIV/AIDS): OR (95% CI): 1.23 (0.84, 1.80)
- 1132 The analysis shows conflicting results in terms of the direction of effects of both studies. However, both results 1133
- are not statistically significant.


### *2.6.4. IC/IS*

#### 2.6.4.1. Supplemental eFigure 8. IC/IS, Death Outcome (No. of Subgroups: 24)



 AIDS, acquired immune deficiency syndrome; CI, confidence interval; HR, hazard ratio; IC/IS, immunocompromising/immunosuppressing; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

## 1139 2.6.4.2. Supplemental eFigure 9. IC/IS, Hospitalization Outcome (No. of Subgroups: 16)




Heterogeneity:  $\chi_{15} = 767.57$  (P < .001),  $I^2 = 98\%$ Test for subgroup differences:  $\chi_3^2 = 3.22$  (P = .36)

1140

1141 1142 1143 AIDS, acquired immune deficiency syndrome; CEV, clinically extremely vulnerable; CI, confidence interval; DMARD, disease-modifying anti-rheumatic drugs; HR, hazard ratio; IC/IS, immunocompromising/immunosuppressive; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

# 1144 2.6.4.3. Supplemental eFigure 10. IC/IS, ICU Admission Outcome (No. of Subgroups: 5)

Study (Subgroup )	RR(95%CI)
strat = HR	
Wang 2023 [Immunocompromised conditions]	4.65 [4.01; 5.39]
strat = IRR	
Evans 2023 [Total broadly defined immunocompromised]	4.13 [3.30; 5.18]
strat = OR	
Beraud 2023 [Immunosuppression]	1.28 [0.70; 2.22]
Briciu 2023 [Immunosuppression]	4.96 [0.65; 25.12]
Nevejan 2022 [Immunocompromised]	3.41 [2.04; 5.68]
Total	2.39 [1.05; 5.46]
Heterogeneity: $\chi_2^2 = 6.91 (P = .03)$ , $I^2 = 71\%$	
Total	3.38 [2.37; 4.83]




Heterogeneity:  $\chi_4^2 = 18.80 \ (P < .001), \ l^2 = 79\%$ Test for subgroup differences:  $\chi_2^2 = 2.93 \ (P = .23)$  p-value:<0.05

1145

CI, confidence interval; HR, hazard ratio; IC/IS, immunocompromising/immunosuppressing; ICU, intensive care unit; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

#### 1148 2.6.4.4. Supplemental eFigure 11. IC/IS, Combined Outcome (No. of subgroups: 17)




Test for subgroup differences:  $\chi_2^2 = 0.88 \ (P = .64)$ 

1149

CI, confidence interval; HR, hazard ratio; IC/IS, immunocompromising/immunosuppressing; IRR, incidence rate ratio; OR, odds ratio; RR,

#### 1152 2.6.5. Liver Disease

#### 1153 2.6.5.1. Supplemental eFigure 12. Liver Disease, Death Outcome (No. of Subgroups: 14)



Heterogeneity:  $\chi_{13}^2 = 311.78 (P < .001), I^2 = 96\%$ Test for subgroup differences:  $\chi_2^2 = 38.68 \ (P < .001)$  p-value:<0.05


1154

1155

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

- 1156 2.6.5.2. Liver Disease, Hospitalization Outcome (No. of Studies: 1; No. of Subgroups: 2)
- 1157 The studies reported the following results for the 'Hospitalization' outcome in the 'Liver disease' populations:
- Hippisley-Cox 2023<sup>40</sup> (women with liver cirrhosis): HR (95% CI): 2.40 (1.97, 2.92)
- Hippisley-Cox 2023<sup>40</sup> (men with liver cirrhosis): HR (95% CI): 2.18 (1.80, 2.63)
- Both liver cirrhosis subgroups in the Hippisley-Cox 2023 study found statistically significant increases in the risk of 'Hospitalization'.

## 1162 2.6.5.3. Supplemental eFigure 13. Liver Disease, ICU Admission Outcome (No. of Subgroups: 5)




1163

1100

CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; IRR, incidence rate ratio; NA, not applicable; OR, odds ratio; RR, risk

# 1166 2.6.5.4. Supplemental eFigure 14. Liver Disease, Combined Outcome (No. of Subgroups: 11)

Study (Subgroup )	RR(95%CI)
strat = HR	
Bedston 2024 [Liver Cirrhosis]	2.29 [1.74; 3.00]
strat = OR	
Guo 2023 [ Chronic liver disease ]	1.18 [0.34; 4.04]
Li 2023 [ Chronic liver disease ]	0.44 [0.09; 2.10]
Lu 2022 [Hepatic disease]	5.77 [0.66; 50.29]
Vo 2022 [Liver disease cirrhosis and other liver conditions except viral hepatitis]	1.31 [1.13; 1.53]
Vo 2022 [ Viral hepatitis ]	0.89 [0.70; 1.13]
Total	1.10 [0.77; 1.56]
Heterogeneity: $\chi_4^2 = 10.72 \ (P = .03), \ I^2 = 63\%$	
strat = RR	
Agrawal 2022 [Liver Cirrhosis]	3.34 [3.04; 3.68]
Griggs 2024 [ Unvaccinated-BA1-Hepatic ]	1.35 [1.23; 1.49]
Griggs 2024 [ Unvaccinated-Post BA1-Hepatic ]	1.32 [1.17; 1.50]
Griggs 2024 [Vaccinated-BA1-Hepatic]	1.23 [1.05; 1.44]
Griggs 2024 [ Vaccinated-Post BA1-Hepatic ]	1.51 [1.36; 1.68]
Total	1.62 [1.09; 2.40]
Heterogeneity: $\chi_4^2 = 250.36 \ (P < .001), \ I^2 = 98\%$	
Total	1.50 [1.12; 2.00]



p-value:<0.05

Heterogeneity:  $\chi^2_{10}$  = 298.69 (P < .001),  $I^2$  = 97% Test for subgroup differences:  $\chi^2_2$  = 10.55 (P = .005)


1167

1168

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

#### 1169 *2.6.6. Renal Disease*

### 1170 2.6.6.1. Supplemental eFigure 15. Renal Disease, Death Outcome (No. of Subgroups: 44)




1171

1172

CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

## 1173 2.6.6.2. Supplemental eFigure 16. Renal Disease, Hospitalization Outcome (No. of Subgroups: 17)




1174

1175

CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

#### 1176 2.6.6.3. Supplemental eFigure 17. Renal Disease, ICU Admission Outcome (No. of Subgroups: 10)




Heterogeneity:  $\chi_9^2 = 227.65 (P < .001), I^2 = 96\%$ 

Test for subgroup differences:  $\chi_2^2$  = 144.35 (P < .001)

1177

CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; ICU, intensive care unit; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

### 1180 2.6.6.4. Supplemental eFigure 18. Renal Disease, Combined Outcome (No. of Subgroups: 21)



Heterogeneity:  $\chi^2_{20}$  = 392.46 (P < .001),  $I^2$  = 95% Test for subgroup differences:  $\chi^2_2$  = 4.44 (P = .11)

1181

1182

CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio.

#### 1183 2.6.7. Transplant

#### 1184 2.6.7.1. Supplemental eFigure 19. Transplant, Death Outcome (No. of Subgroups: 13)


Study (Subgroup )	RR(95%CI)				
strat = HR					
Hippisley-Cox 2023 [ Women with marrow transplant ]	5.64 [ 1.04; 30.72]			-	$\dot{+}$
Hippisley-Cox 2023 [ Women with SOT ]	5.83 [ 2.49; 13.63]				÷
Hippisley-Cox 2023 [ Men with marrow transplant ]	0.84 [ 0.11; 6.67]			<del> </del>	-
Hippisley-Cox 2023 [Men with SOT]	2.36 [ 0.86; 6.50]		-	-	-
Nab 2023 [Wave 4: Kidney transplant]	18.40 [14.55; 23.27]				
Nab 2023 [ Wave 4: Other organ transplant ]	9.92 [ 6.39; 15.39]				<del>! •</del>
Nab 2023 [Wave 5: Kidney transplant]	18.03 [10.63; 30.59]				
Nab 2023 [ Wave 5: Other organ transplant ]	2.49 [ 0.35; 17.71]			<b>-</b>	<del>!</del>
Total	7.42 [ 4.19; 13.14]			_	$\dot{-}$
Heterogeneity: $\chi_7^2 = 35.72 \ (P < .001), I^2 = 80\%$					
strat = OR					
Chen 2024 [ Organ transplantation ]	1.70 [ 0.30; 8.20]			-	÷
de Prost 2022 [Immunosuppression (3 category) SOT]	2.49 [ 1.07; 5.80]				
Total	2.30 [ 1.08; 4.88]				
Heterogeneity: $\chi_1^2 = 0.16$ ( $P = .69$ ), $I^2 = 0\%$					
strat = RR					
Evans 2023 [SOT ≤5 years prior ]	13.03 [ 9.22; 18.41]				-
Evans 2023 [SCT ≤2 years prior ]	6.36 [ 1.55; 26.18]				$\leftarrow$
Overvad 2022 [Total SOTRs]	7.40 [ 3.70; 14.80]			—	-
Total	10.44 [ 6.79; 16.06]				<
Heterogeneity: $\chi_2^2 = 2.72$ ( $P = .26$ ), $I^2 = 26\%$					
Total	6.78 [ 4.41; 10.43]			<	<u>`</u>
		0.4	0.5	1 0	
		0.1	0.5	1 2	10
Heterogeneity: $\chi_{12}^2 = 59.59 (P < .001), I^2 = 80\%$				p-value:<0.05	
T1 ( the th					

Test for subgroup differences:  $\chi_2^2$  = 11.70 (P = .003)

1185

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio; SCT, stem cell transplant; SOT, solid organ transplant; SOTR, solid organ transplant recipients.

## 1188 2.6.7.2. Supplemental eFigure 20. Transplant, Hospitalization Outcome (No. of Subgroups: 8)




1189

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio; SCT, stem cell transplant; SOT, solid organ transplant; SOTR, solid organ transplant recipients.

2.6.7.3. Transplant, ICU Admission Outcome (No. of Studies: 1; No. of Subgroups: 2)
The studies reported the following results for the 'ICU' outcome in the 'Transplant' populations:
Evans 2023<sup>33</sup> (solid organ transplant ≤5 years prior): IRR (95% CI): 24.74 (14.28, 42.85)
Evans 2023<sup>33</sup> (stem cell transplant ≤2 years prior): IRR (95% CI): 24.92 (6.03, 102.98)
Both 'Transplant' subgroups in the Evans 2023 study found statistically significant increases in the risk of the 'ICU' outcome. However, both subgroups, the 'Stem cell transplant' subgroup in particular, had very wide CIs, indicating a low number of 'Transplant' participants who were admitted to the ICU.

## 1199 2.6.7.4. Supplemental eFigure 21. Transplant, Combined Outcome (No. of Subgroups: 5)



Heterogeneity:  $\chi_4^2 = 149.38 \ (P < .001), I^2 = 97\%$ Test for subgroup differences:  $\chi_1^2 = 1.97 \ (P = .16)$ 

1200

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, risk ratio; SCT, stem cell transplant; SOT, solid organ transplant; SOTR, solid organ transplant recipients.

#### 1203 References

- 1204 1. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):210.
- Wells G SB, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp.
- 1209 3. JBI. Critical appraisal tools. <a href="https://jbi.global/critical-appraisal-tools">https://jbi.global/critical-appraisal-tools</a>.
- **4.** Greenland S. Quantitative methods in the review of epidemiologic literature. *Epidemiol Rev.* 1987;9:1-30.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.
- Higgins JPT TJ, Chandler J, Li T, Page MJ, Welch V, eds. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Version 6.4 Cochrane, updated August 2023. [cited 2024 May 28].

  Available from: https://training.cochrane.org/handbook/current.
- Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test.
  Asymmetry detected in funnel plot was probably due to true heterogeneity. *BMJ*. 1998;316(7129):469; author reply 470-461.
- Starkey T, Ionescu MC, Tilby M, et al. A population-scale temporal case—control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP). *Sci Rep.* 2023;13(1):11327.
- Russell SL, Klaver BRA, Harrigan SP, et al. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada. *J Med Virol*. 2023;95(1):e28423.
- 1225 10. Mayer C, Woo MS, Brehm TT, et al. History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study. *Eur J Neurol*. 2023;30(8):2297-2304.
- 1228 World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern.
  Updated November 26, 2021.<a href="https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern">https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern</a>. Accessed July 3, 2024.
- 1231 12. Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. *Lancet*. 2022;400(10360):1305-1320.
- 1235 13. AlBahrani S, AlBarrak A, Al-Musawi T, et al. COVID-19 vaccine had a significant positive impact on patients with SARS-COV-2 during the third (Omicron) wave in Saudi Arabia. *J Infect Public Health*. 2022;15(11):1169-1174.
- 1238 14. Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. *Nat Med.* 2022;28(7):1486-1490.
- 1241 15. Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. *Lancet Infect Dis.* 2023;23(8):914-921.
- 1244
  16. Bahremand T, Yao JA, Mill C, et al. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. *Lancet Reg Health Am.* 2023;20:100461.
- 1247 17. Bao S, Lu G, Kang Y, et al. A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave. *Front Med (Lausanne)*. 2022;9:1018516.
- 1249
   1250
   1251
   1252
   1260
   1270
   128. Bedston S, Almaghrabi F, Patterson L, et al. Risk of severe COVID-19 outcomes after autumn 2022
   1251
   1252
   1252
   1253
   1254
   1255
   1256
   1256
   1257
   1258
   1259
   1250
   1250
   1251
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
   1252
- 1253
   19. Benites-Godínez V, Mendoza-Cano O, Trujillo X, et al. Survival analysis and contributing factors among PCR-confirmed adult inpatients during the endemic phase of COVID-19. *Diseases*.
   1255
   1256
- 1256 20. Beppu H, Fukuda T, Otsubo N, et al. Comparative outcomes of hemodialysis patients facing pre-Omicron and Omicron COVID-19 epidemics. *Ther Apher Dial*. 2024;28(1):51-60.

- Beraud G, Bouetard L, Civljak R, et al. Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1). *Clin Microbiol Infect*. 2023;29(5):642-650.
- Bournia V-K, Fragoulis GE, Mitrou P, et al. Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study. *Rheumatology*. 2023;63(4):1130-1138.
- 1263 23. Briciu V, Topan A, Calin M, et al. Comparison of COVID-19 severity in vaccinated and unvaccinated patients during the Delta and Omicron wave of the pandemic in a Romanian tertiary infectious diseases hospital. *Healthcare*. 2023;11(3):373.
- Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the Omicron wave in Israel: benefits of a fourth vaccine dose. *Clin Infect Dis.* 2022;76(3):e234-e239.
- 1269 25. Chen Z, Tian F, Zeng Y. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients. *BMC Geriatrics*, 2023;23(1):774.
- 1271 26. Chen CL, Teng CK, Chen WC, et al. Clinical characteristics and treatment outcomes among the hospitalized elderly patients with COVID-19 during the late pandemic phase in central Taiwan. *J Microbiol Immunol Infect*. 2024;57(2):257-268.
- 1274 27. Choi S-H, Choi JH, Lee JK, et al. Clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea. *J Korean Med Sci*. 2023;38(9):e65.
- de Prost N, Audureau E, Heming N, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. *Nat Commun*. 2022;13(1):6025.
- de Prost N, Audureau E, Préau S, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study. *Intensive Care Med Exp.* 2023;11(1):48.
- 1283
   1284
   1285
   Drummond PD, de Salles DB, de Souza NSH, et al. Profile and outcomes of hospitalized COVID-19 patients during the prevalence of the Omicron variant according to the Brazilian regions: a retrospective cohort study from 2022. *Vaccines*. 2023;11(10):1568.
- Elamin MY, Maslamani YA, Alsheikh FA, et al. Impact of vaccination on morbidity and mortality in adults hospitalized with COVID-19 during the Omicron wave in the Jazan Region, Saudi Arabia. *Saudi Med J.* 2024;45(2):179-187.
- Ellis RJ, Moffatt CR, Aaron LT, et al. Factors associated with hospitalisations and deaths of residential aged care residents with COVID-19 during the Omicron (BA.1) wave in Queensland. *Med J Aust*. 2023;218(4):174-179.
- Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. *Lancet Reg Health Eur.* 2023;35:100747.

1296

- **34.** Favia G, Barile G, Tempesta A, et al. Relationship between oral lesions and severe SARS-CoV-2 infection in intensive care unit patients. *Oral Dis.* 2024;30(3):1296-1303.
- Flacco ME, Acuti Martellucci C, Soldato G, et al. Predictors of SARS-CoV-2 infection and severe and lethal COVID-19 after three years of follow-up: a population-wide study. *Viruses*. 2023;15(9):1794.
- Gazit S, Saciuk Y, Perez G, et al. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. *BMJ*. 2022;377:e071113.
- Griggs EP, Mitchell PK, Lazariu V, et al. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. *Clin Infect Dis.* 2024;78(2):338-348.
- 38. Guo Y, Guo Y, Ying H, et al. In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study. *BMC Infect Dis.* 2023;23(1):698.
- Helmy MA, Milad LM, Hasanin AM, et al. Parasternal intercostal thickening at hospital admission: a promising indicator for mechanical ventilation risk in subjects with severe COVID-19. *J Clin Monit Comput.* 2023;37(5):1287-1293.
- Hippisley-Cox J, Khunti K, Sheikh A, Nguyen-Van-Tam JS, Coupland CAC. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. *BMJ*. 2023;381:e072976.

- Jamaati H, Karimi S, Ghorbani F, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: a national cohort study in Iran. *J Med Virol*. 2023;95(3):e28607.
- 1317
  1318
  1319
  42. Kang J-M, Kang M, Kim Y-E, et al. Severe coronavirus disease 2019 in pediatric solid organ transplant recipients: big data convergence study in Korea (K-COV-N cohort). *Int J Infect Dis*. 2023;134:220-227.
- 1320
   1321
   1321
   1322
   43. Karageorgou V, Papaioannou AI, Kallieri M, et al. Patients hospitalized for COVID-19 in the periods of Delta and Omicron variant dominance in Greece: determinants of severity and mortality. *J Clin Med*. 2023;12(18):5904.
- 1323 44. Kim SH, Kim T, Choi H, Shin TR, Sim YS. Clinical outcome and prognosis of a nosocomial outbreak of COVID-19. *J Clin Med*. 2023;12(6):2279.
- 1325 45. Klein EY, Fall A, Norton JM, et al. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis. *J Clin Virol*. 2023;165:105500.
- 1327
   1328
   1329
   Konermann FM, Gessler N, Wohlmuth P, et al. High in-hospital mortality in SARS-CoV-2-infected patients with active cancer disease during Omicron phase of the pandemic: insights from the CORONA Germany study. *Oncol Res Treat*. 2023;46(5):201-210.
- Lee CM, Kim M, Park SW, et al. Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era. *Infect Dis (Lond)*. 2024;56(2):116-127.
- Li H, Jia X, Wang Y, et al. Differences in the severity and mortality risk factors for patients hospitalized for COVID-19 pneumonia between the early wave and the very late stage of the pandemic. *Front Med (Lausanne)*. 2023;10:1238713.
- Li D-J, Zhou C-C, Huang F, Shen F-M, Li Y-C. Clinical features of omicron SARS-CoV-2 variants infection associated with co-infection and ICU-acquired infection in ICU patients. *Front Public Health*. 2024;11:1320340.
- Liu Y, Qi Z, Bai M, et al. Combination of chest computed tomography value and clinical laboratory data for the prognostic risk evaluation of patients with COVID-19. *Int J Gen Med*. 2023;16:3829-3842.
  Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes
  - **51.** Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. *Emerg Microbes Infect*. 2022;11(1):2045-2054.
- Mendoza-Cano O, Trujillo X, Ríos-Silva M, et al. Association between vaccination status for COVID-19 and the risk of severe symptoms during the endemic phase of the disease. *Vaccines*. 2023;11(10):1512.

1353

- Mizrahi Reuveni M, Kertes J, Shapiro Ben David S, et al. Risk stratification model for severe COVID-19 disease: a retrospective cohort study. *Biomedicines*. 2023;11(3):767.
- Morris CP, Eldesouki RE, Sachithanandham J, et al. Omicron subvariants: clinical, laboratory, and cell culture characterization. *Clin Infect Dis.* 2023;76(7):1276-1284.
- 1349
  1350
  1351
  1352
  136.
  136.
  137.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  138.
  139.
  139.
  139.
  139.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.
  130.</l
  - Nevejan L, Ombelet S, Laenen L, et al. Severity of COVID-19 among hospitalized patients: Omicron remains a severe threat for immunocompromised hosts. *Viruses*. 2022;14(12):2736.
- 1354 57. O'Leary AL, Wattengel BA, Carter MT, Drye AF, Mergenhagen KA. Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance. *Am J Infect Control*. 2023;51(6):603-606.
- Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study. *Am J Transplant*. 2022;22(11):2627-2636.
- Parajuli P, Sabo R, Alsaadawi R, et al. Fibrosis-4 (FIB-4) index as a predictor for mechanical ventilation and 30-day mortality across COVID-19 variants. *J Clin Transl Sci.* 2023;7(1):e213.
- Parra-Bracamonte GM, Lopez-Villalobos N, Velazquez MA, et al. Comparative analysis of risk factors for COVID-19 mortality before, during and after the vaccination programme in Mexico. *Public Health*. 2023;215:94-99.
- Patton MJ, Orihuela CJ, Harrod KS, et al. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. *Crit Care*. 2023;27(1):34.
- Puyat JH, Fowokan A, Wilton J, et al. Risk of COVID-19 hospitalization in people living with HIV and HIV-negative individuals and the role of COVID-19 vaccination: a retrospective cohort study. *Int J Infect Dis.* 2023;135:49-56.

- 1370 **63.** Radhakrishnan N, Liu M, Idowu B, et al. Comparison of the clinical characteristics of SARS-CoV-2 1371 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. BMC 1372 Infect Dis. 2023;23(1):747.
- 1373 Rasmussen LD, Cowan S, Gerstoft J, et al. Outcomes following severe acute respiratory syndrome **64.** 1374 coronavirus 2 infection among individuals with and without HIV in Denmark. AIDS. 2023;37(2):311-1375
- 1376 **65.** Risk M, Hayek SS, Schiopu E, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) 1377 variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective 1378 cohort study. Lancet Rheumatol. 2022;4(11):e775-e784.
- 1379 Shakor ASaA, Samsudin EZ, Chen XW, Ghazali MH. Factors associated with COVID-19 brought-in 66. 1380 deaths: a data-linkage comparative cross-sectional study. J Infect Public Health. 2023;16(12):2068-1381 2078.
- 1382 **67.** Shi HJ, Yang J, Eom JS, et al. Clinical characteristics and risk factors for mortality in critical COVID-1383 19 patients aged 50 years or younger during Omicron wave in Korea: comparison with patients older 1384 than 50 years of age. J Korean Med Sci. 2023;38(28):e217.
- 1385 **68.** Simmons AE, Amoako A, Grima AA, et al. Vaccine effectiveness against hospitalization among 1386 adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: 1387 a retrospective cohort study. PLoS One. 2023;18(3):e0283715.

1389

1390

1391

1392

1393

1394

1395

1418

- 69. Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12:100297.
- 70. Svensson ALL, Emborg H-D, Bartels LE, et al. Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study. Ann Rheum Dis. 2023;82(10):1359-1367.
- 71. Tsujimoto Y, Kobayashi M, Oku T, et al. Outcomes in novel hospital-at-home model for patients with 1396 COVID-19: a multicentre retrospective cohort study. Fam Pract. 2023;40(5-6):662-670.
- 1397 **72.** Vo AD, La J, Wu JT, et al. Factors associated with severe COVID-19 among vaccinated adults treated 1398 in US veterans affairs hospitals. JAMA Netw Open. 2022;5(10):e2240037.
- 1399 **73.** Wang X, Zein J, Ji X, Lin DY. Impact of vaccination, prior infection, and therapy on Omicron 1400 infection and mortality. J Infect Dis. 2023;227(8):970-976. 1401
- 74. Ward IL, Robertson C, Agrawal U, et al. Risk of COVID-19 death in adults who received booster 1402 COVID-19 vaccinations in England. Nat Commun. 2024;15(1):398.
- 1403 *75*. Xin S, Chen W, Yu O, Gao L, Lu G. Effect of the number of coronavirus disease 2019 (COVID-19) 1404 vaccination shots on the occurrence of pneumonia, severe pneumonia, and death in SARS-CoV-2-1405 infected patients. Front Public Health. 2024;11:1330106.
- 1406 Xing Y, Sun Y, Tang M, et al. Variables associated with 30-day mortality in very elderly COVID-19 **76.** 1407 patients. Clin Interv Aging. 2023;18:1155-1162.
- 1408 77. Yang H, Wang Z, Zhang Y, et al. Clinical characteristics and factors for serious outcomes among 1409 outpatients infected with the Omicron subvariant BF.7. J Med Virol. 2023;95(8):e28977.
- 1410 **78.** Zhang Y, Han J, Sun F, et al. A practical scoring model to predict the occurrence of critical illness in 1411 hospitalized patients with SARS-CoV-2 omicron infection. Front Microbiol. 2022;13:1031231.
- 1412 **79.** Zhao Q, Zheng B, Han B, et al. Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy 1413 and safety for hospitalized patients with COVID-19? a retrospective cohort study. *Infect Dis Ther*. 1414 2023;12(8):2087-2102.
- 1415 Zhu Z, Cai J, Tang Q, et al. Circulating eosinophils associated with responsiveness to COVID-19 80. 1416 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection. BMC Pulm 1417 Med. 2023;23(1):177.